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"to strive, to seek, to find, and not to yield"
Alfred, Lord Tennyson
3SUMMARY
There is evidence from clinical and experimental studies 
of a two-way relationship between cancer and the 
haemostatic system. Human cancer is associated with 
activation of haemostatic mechanisms, whilst animal 
studies of coumarin effects on metastasis suggest that 
coagulation may be implicated in the metastatic process. 
Warfarin inhibits, whilst the warfarin-dependent 
coagulation factor complex II, IX, X enhances, pulmonary 
tumour seeding in an animal model of metastasising 
mammary carcinoma. The purpose of this study was to 
investigate the mechanisms responsible for this effect 
of tumour enhancement by the coagulation factor complex 
II (prothrombin), IX, X. Initially, preliminary 
experiments were performed to validate the experimental 
tumour model used by previous workers. In particular, 
the effect of the factor complex II, IX, X on tumour 
cell aggregability and the influence of the timing and 
dose of administration of the factor complex on 
pulmonary metastasis were studied. The results of these 
experiments validated the results obtained by previous 
workers.
In order to exclude the possibility that this effect 
of tumour enhancement by the factor complex is secondary 
to it's xenogeneic properties, a comparison was made 
between the prometastatic effects of human and rat 
coagulation factor complexes. The results of this 
experiment showed that both rat and human factor
4complexes enhanced pulmonary tumour seeding to an equal 
degree.
In order to assess changes at the level of the 
pulmonary microcirculation on administration of tumour 
cells and the factor complex II, IX, X, a further study 
was performed to look at the passage of radiolabelled 
tumour cells through the pulmonary microcirculation. 
This study demonstrated a 20% increase in the number of 
tumour cells trapped in the lungs within the first hour 
of tumour cell and factor complex administration, when 
compared with the group that received tumour cells 
alone. These results suggest that an intravascular event 
may be responsible for the enhancement of metastasis 
previously demonstrated.
Further animal studies demonstrated that individual 
purified components of the factor complex II, IX, X, and 
various combinations thereof, enhanced pulmonary tumour 
seeding to a similar degree. This suggests that they may 
do so via a common pathway (factor II), involving 
activation of the coagulation system. Evidence for 
activation of coagulation was demonstrated by estimating 
plasma fibrinopeptide A, a highly sensitive indicator of 
activation of the coagulation system.
Based on these results, we hypothesised that factors 
II, IX, X, enhanced metastasis by encouraging tumour 
cell entrapment within a fibrin clot, in the pulmonary 
microcirculation. In a further experiment we 
demonstrated that fibrinolysis, using a "clot-lysis" 
dose of intravenous Streptokinase, reversed this effect
5of tumour enhancement. Furthermore, intravenous 
Streptokinase inhibited pulmonary tumour seeding even in 
the absence of exogenous factor complex II, IX, X. This 
inhibitory effect of Streptokinase on tumour seeding may 
have clinical implications with regard to the 
prescription of antimetastatic therapy in cancer 
patients.
6CONTENTS
PRELIMINARY MATERIAL
List of Abbreviations 
Acknowledgement s 
Declaration
INTRODUCTION PAGE
1. THE MECHANISM OF METASTASIS
1.1 The metastatic process 14
1.2 Metastatic heterogeneity of malignant 
neoplasms 21
2. THE HAEMOSTATIC SYSTEM
2.1 The coagulation system 23
2.2 Pathways of blood coagulation 25
2.3 The fibrinolytic system 29
2.4 The role of platelets 35
2.5 The role of vitamin K 37
2.6 Measurements of the coagulation system 38
3. CANCER AND THE COAGULATION SYSTEM
3.1 Evidence for altered coagulation in 
malignant disease 41
3.2 The role of fibrin and the fibrinolytic
system in malignant disease 44
3.3 The role of platelets in malignant disease 46
3.4 Procoagulant activity of tumour cells 4 9
3.5 Summary of evidence and hypothesis 52
CHAPTER 1. VALIDATION OF PREVIOUS WORK AND THE 
ANIMAL MODEL OF METASTATIC CARCINOMA
Introduction 57
Metastatic tumour model 60
Studies to validate previous work 69
Results 71
Discussion 73
7CHAPTER 2. STUDIES TO DETERMINE WHETHER THE XENOGENEIC 
NATURE OF THE FACTOR COMPLEX IS RESPONSIBLE 
FOR THIS EFFECT OF TUMOUR ENHANCEMENT
Introduction 7 6
Preparation of syngeneic rat factor complex 77
Experiment 79
Results 80
Discussion 80
CHAPTER 3. STUDIES TO DETERMINE WHETHER THE EFFECT 
OF TUMOUR ENHANCEMENT BY FACTOR COMPLEX 
II,IX,X, IS SECONDARY TO INCREASED 
PULMONARY ENTRAPMENT OF TUMOUR CELLS
Introduction 84
Radiolabelling of tumour cells 84
Pilot Studies 86
Experiment 99
Discussion 102
CHAPTER 4. STUDIES TO IDENTIFY WHICH COMPONENT OF THE 
FACTOR COMPLEX II, IX, X, IS RESPONSIBLE 
FOR ENHANCEMENT OF TUMOUR METASTASIS
Introduction 106
Materials and methods 107
Experiment 108
Results 109
Discussion 110
CHAPTER 5. STUDIES TO DETERMINE WHETHER METASTATIC 
TUMOUR ENHANCEMENT OCCURS SECONDARY 
TO ACTIVATION OF THE COAGULATION SYSTEM
Introduction 114
Measurement of Urinary Fibrinopeptide A 115
Measurement of Plasma Fibrinopeptide A 119
Experiment 121
Results 123
Discussion 123
8CHAPTER 6. DOES THE EFFECT OF ENHANCEMENT OF TUMOUR 
METASTASIS BY FACTOR COMPLEX II, IX, X 
REQUIRE THE FORMATION OF A FIBRIN CLOT
Introduction 128
Assays to assess cytotoxicity of Streptokinase 130 
Experiment 133
Results 135
Discussion 135
CHAPTER 7. STUDIES TO DETERMINE THE EFFECT OF
FIBRINOLYSIS ON PULMONARY TUMOUR SEEDING
Introduction 141
Experiment 1 142
Experiment 2 143
Discussion 145
FINAL DISCUSSION
REFERENCES
9LIST OF TABLES AND ILLUSTRATIONS
Tables: Page
1 Coagulation factors in humans 24
2 Components of the fibrinolytic system 32
3 Tests of coagulation 39
4 Validation of Wexler's method 67
5 Effect of factor complex on cell aggregability 74
6 Radiolabelling of different doses of cells 93
7 Uptake of isotope by tumour cells 98
8 Analysis of rat urinary fibrinopeptide A 118
9 Analysis of rat plasma fibrinopeptide A 122
10 The effect of Streptokinase on tumour cells -
clonogenic assay 132
Figures:
1 Major reactions of the coagulation pathway 26
2 Major reactions of the fibrinolytic system 30
3 Morphology of Mtln^ rat mammary carcinoma
cells in tissue culture 59
4 Rat lungs with multiple subpleural tumour
deposits prepared by the method of Wexler 63
5 Histology of pulmonary tumour deposit
a.Peribronchial tumour deposit 64
b.Tumour underlying bronchial epithelium 65
6 Factor complex/tumour cells - dose and time
response 72
7 Effect of rat factor and human factor complex
on pulmonary tumour seeding 81
8 Clonogenic assay 89
9 Results of microtiter assay - day 1 90
10 Results of microtiter assay - day 2 91
10
11 Tumorigenecity of radiolabelled cells 96
12 Pulmonary entrapment of radiolabelled
tumour cells 101
13 Effect of individual factors on pulmonary
tumour seeding 111
14 Analysis of plasma fibrinopeptide A 124
15 Effect of Streptokinase on pulmonary
tumour seeding 136
16 Streptokinase - dose response 144
17 Fibrinolysis and tumour metastasis 146
11
LIST OF ABBREVIATIONS
ADP Adenosine Diphosphate
APC Activated Protein C
ATP Adenosine Triphosphate
BSA Bovine Serum Albumin
DIC Disseminated Intravascular Coagulation
FCS Foetal Calf Serum
FDP Fibrin(ogen) Degradation Products
FpA Fibrinopeptide A
F344 Fischer 344
F10/DMEM 1:1 mixture of Hams' F10 and
Dulbecco's Modified Eagles' Medium
HMW-kininogen High Molecular Weight-kininogen
125judr ^-^^I-iodo-2' -deoxyuridine
MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide
t-PA Tissue Plasminogen Activator
u-PA Urokinase-type Plasminogen Activator
12
ACKNOWLEDGEMENTS
I would like to express my thanks to the following 
people who made this thesis possible:
The Cancer Research Campaign for their generous 
financial support
Dr RJ Perry of the Scottish Blood Transfusion Service 
who supplied me with the Factor concentrates used in all 
the experiments
Dr I McGregor for his advice and helpful criticism with 
the Fibrinopeptide A study (Headquarters Unit 
Laboratory, National Blood Transfusion Service, 
Edinburgh)
Dr J Plumb of Medical Oncology, Garscube, for her 
assistance with tissue culture
Drs G Murray and J Findlay of the Statistics Unit, 
Department of Surgery, for their help with analysis of 
data
Mr T H Cavanagh and his colleagues at the Department of 
Haematology, Western Infirmary for their assistance
The technicians in the Department of Surgery, Western 
Infirmary, in particular Mr C Hughes and Mr A MacIntyre
Dr E Mallon Western Infirmary, for her help with 
histopathology
In particular I would like to thank Mr P McCulloch for 
his advice, helpful criticism, patience and support 
during the last 2 years.
Finally I would like to thank Professor WD George for 
giving me the opportunity to perform these studies, and 
for bearing with me until their completion.
13
DECLARATION
I declare that this thesis has been composed by myself, 
and that the work described herein was performed by me, 
or by myself in conjunction with others. The laboratory 
tests for analysis of Fibrinopeptide A, described in 
Chapter 5, were performed by Drs I McGregor and 0 
Drummond, Headquarters Unit Laboratory, National Blood 
Transfusion Service, Edinburgh. The remaining tests of 
haemostasis described in this thesis were performed by 
Mr T Cavanagh and his colleagues, Department of 
Haematology, Western Infirmary. Preparation of 
microscopic slides illustrated in Chapter 1 were 
performed by Dr E Mallon, Department of Pathology, 
Western Infirmary. Statistical analysis of all the work 
described were supervised by Drs G Murray and J Findlay, 
Medical Statistics, University Department of Surgery, 
Western Infirmary. All other work described herein was 
performed entirely by myself. This work has not been 
presented at any previous application for a degree by 
myself or others.
Papers pertaining to the work described in this thesis 
have been presented at the following meetings of 
scientific societies:
British Association of Surgical Oncology, London, 
November 1990
Surgical Research Society, London, January 1991 
Surgical Research Society, Lancaster, July 1991 
Scottish Society for Experimental Medicine, Edinburgh, 
November, 1991
Publications:
Enhancement of pulmonary tumour seeding by human 
coagulation factors II, IX, X - an investigation into 
the possible mechanisms involved. Purushotham AD, 
McCulloch PG, George WD. Br J Cancer 1991; 64: 513-7.
14
INTRODUCTION:
1. THE MECHANISM OF TUMOUR METASTASIS.
1.1 The metastatic process.
Metastasis has been defined as the "transfer of disease 
from one organ or part to another not directly connected 
with it. It may be due either to the transfer of 
pathogenic organisms or to transfer of cells as in 
malignant tumours" (Dorland, 1965). The major 
significance of metastasis in modern clinical medicine 
is in neoplastic disease. Malignant tumours differ by 
definition from benign tumours because of their capacity 
to metastasise. In clinical oncology, it is this 
dissemination of tumour cells, leading to widespread 
metastatic disease, that is responsible for most 
therapeutic failures. Understanding the underlying 
biology and behavioural aspects of cancer metastasis 
would help to formulate successful therapy in 
disseminated malignancy. The mechanisms responsible for 
tumour cell dissemination are complex and although 
recent research has provided considerable insight into 
the understanding of these mechanisms, much remains to 
be learned about this fascinating aspect of cancer 
biology.
Metastasis can occur either via the lymphatic 
channels or via the bloodstream (haematogenous). In the 
former case, regional lymph nodes are involved whilst in 
the latter, the tissue of distant organs such as liver,
15
lungs, brain or bone is invaded. Haematogenous 
metastasis results in parenchymal destruction leading to 
major organ dysfunction and ultimately death. Tumour 
cell spread can also take place by direct extension or 
by migration of cells trans-coelomically, but such 
routes of dispersion are secondary in importance to 
those involving lymphatic or haematogenous spread. Early 
theories of metastasis viewed metastasis as occurring 
primarily via the lymphatic system and only from there 
to the bloodstream (Halstead, 1907; Handley, 1922). This 
theory has been largely discredited since it is now well 
recognised that carcinomas frequently invade blood 
vessels directly and this has been demonstrated in 
pathological studies (Friedell et al, 1965). In 
addition, circulating cancer cells have been 
demonstrated in the blood stream of cancer patients even 
when there is no gross involvement of regional lymph 
nodes (Salsbury, 1975) . It is now recognised that the 
lymphatic and venous systems are intimately 
interconnected and that cancer cells can invade the 
bloodstream independently of the lymphatics (Fisher & 
Fisher, 1967). It is therefore widely accepted that 
tumour metastasis via the lymphatics and the bloodstream 
occur in parallel and the pattern of this dissemination 
is dependent on the basic biological behaviour of the 
tumour cell line in question.
The development of a metastatic lesion represents 
the outcome of a series of sequential interactions 
between the tumour cell and the hosts defences. For a
16
metastasis to develop, the tumour cell has to
successfully survive a variety of potentially lethal 
confrontations which might be regarded as part of the 
host's defence against metastasis.
During the process of haematogenous metastasis,
tumour cells must invade the bloodstream at one point
and emerge from it at another. There is sufficient 
evidence to suggest that this process occurs in a series 
of stages, each stage posing an obstacle to further 
passage of the tumour cell. Only a small proportion of 
tumour cells eventually survive this process to become 
metastases (Poste & Fidler, 1980). The important steps 
in metastasis are (a) Invasion of host tissue by tumour 
cells with penetration of blood vessels and/or
lymphatics, (b) Detachment of tumour cells and the 
subsequent transport of tumour cell emboli in the
circulation to distant organs, (c) Arrest of the tumour
cells, that survive this process, in the 
microcirculation of target organs, (d) Adherence to 
endothelium/basement membrane of blood vessels and 
subsequent extravasation of cells, (e) Establishment of 
micrometastasis by proliferation of malignant cells and 
(f) Angiogenesis to form macrometastasis.
To produce detectable lesions, metastases must 
develop a vascular network and evade the host immune 
system. Once this has been achieved, tumour cells can
invade host stroma, penetrate blood vessels, and enter
the circulation to produce additional metastases. The 
relative importance of each step in limiting the number
17
of cells which eventually become metastases is 
uncertain, and probably varies under different 
circumstances.
Tumour cell invasion:
Several mechanisms regulate tumour cell invasion of host 
tissues. Tumour cells may pass between endothelial cells 
(Sindelar et al, 1975) or alternatively a group of cells 
may create a breach in the vessel wall (Locker et al, 
1970). Rapidly proliferating tumours may by mechanical 
pressure, force cords of tumour cells along lines of 
least tissue resistance. However, even in the absence of 
pressure factors, many malignant tumours infiltrate host 
tissue (Easty & Easty, 1974; Mareel, 1983). In some 
tumours, cells may invade tissue by virtue of their own 
motility (Strauli & Haemmerli, 1984). In addition, many 
malignant neoplasms express higher levels of lytic 
enzymes such as Cathepsin B and plasminogen activator, 
than do benign tumours or corresponding normal tissue 
(Sloane et al, 1982; Sloane, 1990; Jones & DeClerck, 
1982; Salo et al, 1983) . Destruction of host tissue by 
these enzymes, aided by mechanical pressure caused by a 
rapidly growing tumour mass, probably facilitates
invasion of host tissue by a malignant neoplasm.
To enter and leave the circulation, tumour cells 
penetrate the basement membranes surrounding blood 
vessels. Liotta and colleagues showed that the
constituents of the extracellular matrix can be
destabilised by degradative enzymes secreted by tumour
18
cells (Liotta et al, 1979, 1980; Liotta, 1984, 1986).
Metastatic tumour cells can preferentially attach to the 
major collagen class of basement membranes, type IV 
collagen, and it has been shown that they often can 
secrete high amounts of a collagenase, specific for type 
IV collagen (Woolley, 1984). Other workers have shown 
that metastatic tumour cells can also produce high 
amounts of enzymes capable of cleaving the major 
proteoglycan of basement membranes (Nakajima et al,
1983) .
Transport of tumour cells:
The entry of tumour cells into the circulation does not 
in itself constitute metastasis since most tumour cells 
that enter the circulation die (Fidler, 1970; Weiss, 
1986). Using tumour cells radiolabelled with ^^^1-5- 
Iodo-2T-deoxyuridine, Fidler showed that 24 hours after 
entry into the circulation, <1% of the cells are viable, 
and only <0.1% of all tumour cells in the circulation 
survive to produce metastases (Fidler, 1970). This study 
also showed that the greater the number of cells 
released by a primary tumour the greater the probability 
of metastases developing. Models in which tumour cells 
have been injected intravenously into animals, have 
invariably shown that all surviving tumour cells are 
situated in the lungs suggesting that tumour cells by 
and large are arrested at the first capillary bed that 
they reach (Fidler & Nicolson, 197 6; Proctor, 1976). The 
intravascular phase of tumour metastasis is essentially
19
a phase of attrition, in which most circulating tumour 
cells die. To a great extent this is due to mechanical 
effects: the turbulence of blood flow and the mechanical 
shearing forces, especially during the first passage 
through a capillary bed (Sato & Suzuki, 1976), 
immunological attack by the host defences mainly NK 
(Natural Killer) cells, may also play a role (Fidler et 
al, 197 6b; Weiss et al, 1974) . Aggregation of tumour 
cells with one other, with platelets or with 
lymphocytes, enhances cell survival in the circulation 
(Updyke & Nicolson, 1986; Gasic, 1984; Fidler & Bucana,
1977) .
Tumour cell adhesion and extravasation:
Tumour cell emboli that reach the microcirculation may 
be arrested here, and the ones that survive this process 
can interact with the cells of vascular endothelium. 
Adherence of tumour cells to vascular endothelium may 
occur secondary to mechanical blockage of a small vessel 
by clumps of tumour cells (Roos & Dingemans, 1979) or 
alternatively by stable adhesions between tumour cells 
and vascular endothelial cells (Dvorak et al, 1983). In 
vitro, tumour cells have been shown to adhere 
preferentially to the constituents of the basement 
membrane of the blood vessel rather than to the 
endothelial cells themselves (Nicolson et al, 1985). 
Platelets may facilitate this process via specific 
platelet glycoprotein receptors, lb and the Ilb/IIIa 
complex, which interact with both tumour cells and the
20
subendothelial matrix (Grossi et al, 1987). In addition, 
a platelet secreted protein, thrombospondin, may enhance 
binding of tumour cells to a platelet-fibrin clot or 
alternatively encourage increased mechanical trapping of 
tumour cells (Tuszynski et al, 1987). The trapping of 
tumour cells in the microcirculation, along with the 
formation of a platelet-fibrin clot may result in damage 
to the vascular endothelium, which would further 
encourage tumour cell adhesion to the vessel wall 
(Dvorak et al, 1983).
Following adhesion to the vascular endothelium, 
tumour cells penetrate into the extravascular matrix, 
partly by a process involving enzymatic degradation of 
the basement membrane as described earlier. The 
extravasation of malignant tumour cells into surrounding 
tissues of particular organs may also be due in part to 
selective organ preference (Nicolson et al, 1985). Host 
connective tissue can resist this invasion of tumour 
cells by producing protease inhibitors which can block 
the process of the enzyme-dependent invasion of the 
vascular basement membrane (Liotta, 1986; Woolley,
1984) .
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1.2 Metastatic Heterogeneity of Malignant Neoplasms
It has long been recognised that metastases results from 
the proliferation of a few "seeded" tumour cells in the 
favourable "soil" of selected organs (Paget, 1889).
The current view of the seed-and soil hypothesis 
(Fidler, 1991), consists of three main principles:
a. Different cells from the same neoplasm are 
heterogenous with regard to their metastatic properties.
b. The process of metastasis is selective although it 
contains variable elements
c. The production of metastases is dependent on the 
interaction between metastatic cells and various host 
factors.
Cells with different capacities to metastasise have 
been isolated from parent neoplasms (Fidler, 1973; 
Fidler & Balch, 1987). In 1977, Fidler and Kripke 
demonstrated that different tumour cell clones, each 
from an individual cell isolated from the parent tumour, 
varied quite dramatically in their capacity to produce 
lung tumour seeding following intravenous injection 
(Fidler & Kripke, 1977) . In addition, it has been shown 
that human tumour cell lines of colon and renal cancer 
contain subpopulations of cells with widely varying 
metastatic properties (Fidler, 1986). Further, in vitro 
experiments have demonstrated organ-selective adhesion, 
invasion and growth, offering evidence in support of the 
"seed-soil" hypothesis. Circulatory anatomy and 
haemodynamic factors may also influence the spread of 
malignant cells, as indicated earlier (Weiss, 1980).
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Equally, local immune defences might account for
preferential metastatic growth in target organs (Reif,
1978) . Finally, individual cells within a neoplasm may 
be exposed to different microenvironments, and these 
differences might be responsible for their varying
metastatic potential (Fidler, 1991).
The metastatic process is thus a complex one, 
involving a series of obstacles, each of which a tumour 
cell has to overcome if it is to ultimately form a 
metastatic focus. It is clear that most tumour cells die 
during this process, but those which survive are
potentially lethal to the cancer patient. Although most 
metastases found in clinical practice have been
initiated before diagnosis, there are situations (for 
eg. during operations for cancer) where the prevention 
of metastasis may be clinically useful. It is therefore 
of interest to consider the influences which may 
modulate the metastatic process. In addition to those 
factors already discussed, one major influence is the 
haemostatic system with which the "intravascular" phase 
of the metastatic process is closely linked. The 
coagulation and fibrinolytic pathways influence this 
phase of the metastatic process to a considerable 
degree, as will be outlined later. In order to give a 
clear account of this interaction, it is first necessary 
to describe the role of the haemostatic system under 
normal circumstances.
23
2. THE HAEMOSTATIC SYSTEM
The haemostatic mechanism consists of a series of 
reactions whereby liquid blood is converted to solid 
clot. Under normal circumstances this mechanism is kept 
in balance by the fibrinolytic system, either or both 
being activated or inhibited in appropriate 
circumstances. Macfarlane (1964) and Davie & Ratnoff 
(1964) independently proposed the view that the 
coagulation mechanism is composed of a series of enzyme 
reactions which function as a biological amplifier, each 
factor in turn activating the next factor in the 
sequence by cleaving peptide bonds within it - the so- 
called "cascade" or "waterfall hypothesis". The main 
modulating influences on this process are specific 
inhibitors of activated coagulation factors, the 
fibrinolytic system, platelets and the vascular 
endothelium.
2.1 The Coagulation System:
Coagulation occurs when crossed-linked fibrin is formed. 
This is achieved via a sequence of reactions between 
plasma proteins termed "coagulation factors". The 
various factors in the sequence fall within two 
apparently separate systems only in as much as they are 
stimulated differently - the intrinsic and extrinsic 
systems. In the latter half of the coagulation cascade, 
these two systems join together to act via a common 
pathway, so that irrespective of what the initial 
stimulus is, the final outcome is the same. In recent
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years it has become increasingly clear that these two 
systems are functionally interdependent.
The plasma proteins involved in the process of 
blood coagulation and those that modulate this process 
are listed in Table 1.
All the factors apart from factor VII, are normally 
present in their inactive zymogen form. Following 
activation by limited proteolysis, they exhibit 
increased enzymatic activity and act on the next factor 
in the sequence. Factor VII is present in the active 
form but can only bind to it’s substrate Factor X after 
it reacts with Tissue Factor.
2.2 Pathways of Blood Coagulation:
The relationship between the enzymes making up the 
intrinsic and extrinsic pathways are illustrated in 
figure 1 together with the main interactions known to 
occur between the two systems. Amongst these complex 
relationships, the following are particularly 
noteworthy:
The Intrinsic System:
The stimulus to activation of the intrinsic system 
appears to be the exposure of plasma to a negatively 
charged surface - for eg. glass in vitro, and the 
collagen of damaged blood vessels in vivo. This system 
is initiated by the interaction between four plasma 
proteins - factor XII, Factor XI, prekallikrein and high 
molecular weight kininogen (HMW-kininogen). In the
Note: Interactions 
between 
the 
two 
pathways 
are 
shown 
by 
broken 
arrows
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presence of an anionic surface and kallikrein, Factor 
XII is converted to the two-chain alpha-factor Xlla. The 
optimal activation of factor XII requires prekallikrein, 
HMW-kininogen and an activating surface. Factor Xlla in 
turn activates prekallikrein to form kallikrein which is 
capable of reciprocally activating further surface-bound 
factor XII. This surface-bound factor Xlla proceeds to 
activate factor XI to factor XIa by limited proteolysis.
The mechanism by which a negatively charged surface 
triggers the intrinsic system is as yet unclear. It is 
proposed that the Factor XII zymogen changes in
conformation rendering it vulnerable to proteolysis 
(Griffin, 1978). A detailed study, of the kinetics of
the enzymatic reactions involving the activation of 
factor XII, concluded that reciprocal activation rather 
than autoactivation is the predominant mechanism 
involved.
Kallikrein is also responsible for releasing 
elastase from neutrophils during blood coagulation
(Wachtfogel et al, 1983). It is recognised that elastase 
from granulocytes has the capacity to inactivate factor 
IX (Takaki et al, 1983). This is therefore an additional 
effect of kallikrein on the coagulation system.
The next step in the intrinsic system is the 
activation of factor IX by factor XIa. This step 
requires calcium ions (Amphlett et al, 1981) and results 
in the formation of IXa. Factor IXa, factor VIII, 
negatively-charged phospholipid (from platelets) and 
calcium ions form a complex, in which the enzymatic
28
activity of factor IXa is responsible for activating 
factor X to Xa.
The Extrinsic System
When tissue is damaged, tissue factor is released into 
the bloodstream. This is a lipoprotein consisting of 
apoprotein III and a mixture of phospholipids and when 
bound to Factor VII in the presence of calcium ions 
facilitates binding of Factor VII to it's substrate 
Factor X, which is then activated to Xa. The Factor 
Vll/tissue factor complex is also capable of activating 
factor IX. (Osterud & Rapaport, 1977). Activated factor 
IX can also then activate factor X directly, as 
described above.
The Common Pathway:
The intrinsic and extrinsic pathways converge at the 
level of activation of factor X. The next stage is the 
conversion of prothrombin to form thrombin, a reaction 
catalysed by an enzyme complex termed prothrombinase - a 
combination of activated factor X, factor Va, calcium 
ions and negatively-charged phospholipid. Platelets 
contain 18-25% of the factor V found in blood (Tracy et 
al, 1982) and are the source of phospholipid. Thrombin 
is a potent activator of factor V, but factor Va is 
required for the generation of thrombin. It appears to 
act as a receptor for factor Xa.
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The formation of fibrin:
The coagulation cascade ends in the conversion of 
soluble fibrinogen to insoluble fibrin catalysed by 
thrombin. A fibrin network at the site of injury 
provides stability for a plug of platelets.
Fibrinogen is a dimer with two identical halves each 
consisting of 3 polypeptide chains (A alpha, B beta and 
gamma) . Disulphide bonds also join the two half 
molecules through their A alpha and gamma chains near 
the amino-terminus. During the conversion of fibrinogen 
to fibrin, under the influence of thrombin, the short 
f ibrinopeptides A and B are removed from the amino- 
terminal ends. This exposes the polymerisation sites by 
which the fibrin monomer units crosslink with each other 
(Doolittle, 1977). By the formation of covalent bonds 
between adjacent fibrin monomers, stabilised fibrin is 
produced, a reaction catalysed by calcium ions and 
activated factor XIII. Factor XIII is activated by 
limited proteolysis catalysed by thrombin. Not only does 
cross-linked fibrin possess an increased tensile 
strength, but it is also more resistant to fibrinolysis 
(Folk & Finlayson, 1977).
2.3 The fibrinolytic system: (Fig 2)
The formation of a fibrin clot and it’s subsequent 
degradation is under the control of two closely 
interwoven mechanisms, the coagulation pathway and the 
fibrinolytic pathway. These two systems are in 
constant balance with each other and one or the other is
Note: Broken 
arrows 
represent inhibitory influences
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Figure 
2 
Major reactions 
of the 
fibrinolytic 
system
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activated in appropriate circumstances.
The plasma proteins involved in the process of 
fibrinolysis and those that modulate this process are 
listed in Table 2.
Fibrinolysis involves the conversion of plasminogen 
to plasmin, an enzyme capable of destroying the fibrin 
clot. Plasminogen, a glycoprotein synthesised by liver 
parenchymal cells, is present in blood. Only a part of 
circulating plasminogen is available for binding to 
fibrin. The remainder exists in a reversible bound form 
to histidine-rich glycoprotein and to a minor extent to 
alpha2-antiplasmin.
Activation of plasminogen to plasmin occurs via one 
of two mechanisms: a) via tissue-plasminogen activator
(t-PA) or alternatively b) via urokinase-type 
plasminogen activator (u-PA). The existence of a third 
proactivator, activated by kallikrein and a factor XII- 
dependent pathway and inhibited by Cl-inhibitor, is 
postulated (Kluft, 1980; Kluft et al, 1984). In addition 
to the activator molecules, a series of inhibitors exist 
which interact with the activators via a complex system. 
The way this system functions is understood only in part 
and awaits further investigation.
t-PA is a protease synthesised by the endothelial 
cells of blood vessels (Kristensen et al, 1984). Fibrin 
adsorbs plasmin and t-PA onto itself, thereby bringing 
the necessary components of fibrinolysis in proximity 
with each other and also enhancing the effect of t-PA on 
plasminogen (Bachmann, 1987). In the absence of fibrin,
t-pa: tissue plasminogen activator
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t-PA is incapable of activating significant amounts of 
plasminogen.
u-PA is linked directly to the intrinsic system. 
Factor Xlla in conjuction with HMW-kininogen activates 
prekallikrein to form kallikrein. Kallikrein activates 
the proenzyme pro-urokinase to u-PA, which in turn 
activates plasminogen to form plasmin. Interestingly, 
this interacts closely with the activation of the 
intrinsic system in the coagulation pathway.
Both t-PA and u-PA are inhibited by plasminogen- 
activator inhibitor substances, PAI-1 and PAI-2 
(Bachmann, 1987). These inhibitors of plasminogen- 
activators, particularly PAI-1, act by inhibiting the 
conversion of the weaker proenzyme form (t-PA 1) to the 
more active enzyme form (t-PA 2) and also by directly 
inhibiting the effect of t-PA on plasminogen.
Alpha2-antiplasmin, a glycoprotein synthesised by 
liver parenchymal cells, influences fibrinolysis by 
directly inhibiting plasmin.
Several links between coagulation and fibrinolysis 
have been identified, some of which have been outlined 
above. Activation of the contact system, gives rise to 
the formation of bradykinin from kininogen. Bradykinin 
is a potent inducer of t-PA release from the vascular 
endothelium (Prowse & Cash, 1984) . Two other compounds 
formed during coagulation, thrombin and platelet- 
activating factor, are powerful inducers of t-PA release 
(Emeis & Kluft, 1985).
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The role of Protein C:
Protein C is a vitamin K-dependent plasma protein that 
is converted to it's active form (APC) by thrombin. 
Thrombomodulin, a protein found in the plasma membrane 
of vascular endothelial cells, enhances the thrombin- 
catalysed conversion of APC. APC has two effects:
a. An anticoagulant effect produced by inactivating 
factors V and VIII (Marlar et al, 1981) and
b. An enhancing effect on fibrinolysis (Zolton & 
Seegers, 1973).
The role of Antithrombin III:
Antithrombin III is a major physiological inhibitor of 
thrombin and factor Xa and also inhibits factors IXa, 
XIa and Xlla to a lesser degree. Most of the 
anticoagulant effect of exogenous heparin is mediated 
through it's interaction and stimulation of antithrombin 
III. Heparin Cofactor II is another inhibitor of 
thrombin and it's activity is also stimulated by 
heparin. At high heparin concentrations, it is more 
active than antithrombin III. Other inhibitors of 
coagulation deserving mention are alpha-l-antitrypsin 
(inhibits factor XIa) and Cl inhibitor (inhibits Cl, 
kallikrein, factors XIIA and XIa).
The role of Protein S:
Protein S is a vitamin-K dependent plasma protein but 
not a serine protease. It is chiefly synthesised in the 
liver and also by endothelial cells. 60% of the protein
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S in plasma is found in a 1:1 stoichiometric complex 
with the C4B-binding protein, which regulates the 
activity of the C4 component of complement, and cannot 
react with protein C. The remaining 40% of protein S in 
plasma is in the free form and though having no direct 
inhibitory effects on factors VIII and V, is available 
to form a calcium-dependent complex with activated 
protein C on phospholipids exposed on the surface of 
activated platelets. Like other Vitamin K-dependent 
factors, total protein S is reduced in the newborn. This 
is compensated for by a marked reduction in C4B-binding 
protein so that a relatively normal level of free 
protein S is maintained.
Activated Protein C Inhibitor:
This is a single-chain glycoprotein with several 
features in common with Antithrombin III though
immunologically different from it. It blocks the action 
of it's substrates (activated protein C and to a lesser 
extent thrombin and factor Xa) , forming a 1:1 
inhibitor:protease stoichiometric complex.
2.4 The Role of Platelets
Platelets form an integral part of the coagulation 
system. They participate in several aspects of
haemostasis. Early in the process of haemostasis, 
platelets adhere to the collagen fibres of exposed 
subendothelium of the damaged vessel wall. This
adherence is brought about by the interaction between
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von Willebrand factor and platelet glycoprotein lb or 
the Ilb/IIIa complex or both (Zucker et al, 1977; 
Ruggeri et al, 1983) . Following adhesion, platelets 
undergo a series of reactions beginning initially with a 
loose platelet-platelet attachment. This progresses to 
the "release-reaction" wherein platelets release a 
number of biochemically active mediators from granules 
within their cytoplasm. The dense bodies within 
platelets contain ADP, ATP, serotonin, calcium and 
pyrophosphate. The alpha granules contain the major 
secreted glycoprotein thrombospondin as well as, 
fibrinogen, platelet factor 4, beta-thromboglobulin, 
factor V, factor VIII and platelet-derived growth 
factor. The relevant functions of some of these 
substances, in haemostasis is outlined below:
1. Thrombospondin promotes and strengthens the inter­
platelet bonds.
2. Platelet factor 4 binds to platelet receptors and 
augments aggregation and secretion.
3. Platelet-derived growth factor is a potent 
chemoattractant for monocytes, neutrophils, fibroblasts 
and smooth muscle cells, the cells that participate in 
the repair of the vascular injury.
4. The negatively-charged phospholipids situated in the 
plasma membrane of platelets, calcium ions, factor Va 
and factor Villa are essential for the crucial stages of 
the coagulation cascade as described earlier (activation 
of factor X and the conversion of prothrombin to 
thrombin). The thrombin thus generated stimulates
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further platelet aggregation and release by positive 
feedback.
5. Fibrinogen is the principal interplatelet bridging 
molecule.
The role of ADP in platelet aggregation remains 
controversial. ADP can stimulate platelets and produce a 
change in conformation accompanied by a rise in 
cytosolic calcium. This may lead directly to the binding
of fibrinogen. It has been suggested that there may be
an enzyme with an external nucleotide binding site such
that ADP acts only as an essential co-factor for the
binding of fibrinogen. What is clear however, is that 
ADP is essential for platelet activation to occur.
Finally, platelets promote clot lysis through their 
ability to cause clot contraction (Carroll et al, 1981).
It is clear therefore that platelets have several 
roles to play and are essential for normal haemostasis.
2.5 Role of Vitamin K
This fat soluble vitamin was discovered in 1929. It is 
required for the synthesis of active forms of the 
factors VII, IX, X, and II (prothrombin), as well as the 
coagulation related proteins C, S and Z. Each of these 
proteins contain a series of gamma-carboxy glutamic acid 
residues, and the role of vitamin K is to act as a co­
factor for the production of these residues from 
glutamic acid. The gamma carboxylated residues appear to 
bind to calcium ions, which in turn are responsible for 
binding the proteins to phospholipid bilayers. This
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binding provides vital amplification of the reactions 
catalysed, essential to the rapid production of a fibrin 
clot. Exactly how this occurs is not known, but it is 
believed that binding to this kind of structure may
enhance the probability of substrate and enzyme
approaching each other close enough for catalysis to 
occur.
2.6 Measurements of the coagulation system.
There are several available tests to measure the 
haemostatic system. Some of these are outlined in Table 
3. The overall function of the coagulation system is 
usually measured in terms of the time taken for a fibrin 
clot to form under defined conditions. The simplest
tests, the bleeding and clotting times, are applied to 
whole blood, whilst the conditions for the other tests 
are more complex. The time taken for clot formation 
reflects the efficiency of the mechanism as a whole,
though not as precisely as a direct measurement of the 
rate of fibrin formation would do. The thrombin time, 
activated partial thromboplastin time (APTT) and 
prothrombin time are the most commonly used measures. 
They reflect the activity of the final common pathway to 
fibrin formation, the intrinsic and the extrinsic 
pathways respectively. Measurements of the levels of 
individual factors can be performed using a variety of 
functional assays. They provide relatively limited 
information, as only very major reductions in the levels 
of individual factors are likely to cause changes in the
APTT: Activated 
Partial Thromboplastin Time 
FDP: 
Fibrin(ogen) Degradation 
Products 
FpA: 
Fibrinopeptide A 
ADP: Adenosine diphosphate
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efficiency of coagulation. Haemophiliacs, for example, 
have adequate haemostatic function for normal purposes 
if their level of factor VIII is greater than 30% of 
normal.
Immunological assays for the breakdown products of 
fibrin give a rough measure of the activity of the 
system. The standard assay cannot differentiate between 
the degradation products of fibrin and of fibrinogen. 
High levels of fibrin(ogen) degradation products (FDPs) 
may therefore reflect excessive activity in either the 
coagulation or the fibrinolytic system or both. A more 
sensitive method of monitoring haemostatic function is 
the measurement of specific products of individual 
reactions. An example of this is fibrinopeptide A (FpA), 
a 16 amino-acid peptide cleaved from the alpha chain of 
the fibrin molecule in the first stage of the formation 
of fibrin (Rickies and Edwards, 1983) . It has a short 
half-life of about 3 minutes and therefore gives a 
picture of the level of activation of the coagulation 
system at one precisely defined point in time. The other 
tests used to measure specific alterations in the 
coagulation system are outlined in Table 3.
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3. CANCER AND THE COAGULATION SYSTEM.
3.1 Evidence for altered coagulation in malignant 
disease.
The haemostatic system is altered significantly by 
malignancy. In 1865, Trousseau described an association 
between visceral malignancy and migratory
thrombophlebitis (Trousseau, 1865) . This was the first 
published report of evidence of a disturbance of 
coagulation in cancer patients. Since then, several 
workers have substantiated this evidence by 
demonstrating a disturbance in coagulation in patients 
with malignant disease in a variety of situations 
(Miller et al, 1967; Goodnight, 1974; Hagedorn et al, 
1974; Sack et al, 1977; Bick, 1978; Nand et al, 1987). 
Evidence of thromboembolism is present in up to 50% of 
cancer patients at post-mortem and is related to the 
type of malignancy (Thompson & Rodgers, 1952).
Thrombosis is a more common complication of pancreatic
and gastric cancer than of prostatic or skin cancer 
(Dvorak, 1987). Furthermore, Goldberg et al (1987) 
demonstrated a significantly higher incidence of occult 
malignancy in patients with deep venous thrombosis. It 
is well recognised that patients undergoing surgery for 
cancer, postoperatively, have a 33% risk of deep venous 
thrombosis (Pineo et al, 1974; Negus et al, 1980), as
compared to a risk of 10% in patients with benign 
disease.
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Haemmorhage occurs in about 10% of cancer patients 
but half of these result from thrombocytopaenia due to 
chemotherapy (Belt et al, 1978). Local haemorrhage may 
result from tumour necrosis or direct invasion of blood 
vessels, while more generalised bleeding is due to bone 
marrow involvement or acute Disseminated Intravascular 
Coagulation (DIC) (Dvorak, 1987). Overall,
thromboembolic and haemorrhagic complications are the 
second most common cause of death in cancer patients 
(Ambrus et al, 1975).
DIC, a disorder caused by generalised inappropriate 
activation of the coagulation system within the 
vasculature, results in diffuse haemorrhage due to a 
"consumptive coagulopathy". 8 - 15 % of cancer patients 
with laboratory abnormalities, develop DIC of clinical 
significance (Sack et al, 1977; Weick, 1978; Kies et al, 
1980). However, these represent only the decompensated 
form of DIC (Goldsmith, 1984), with a much larger 
proportion of patients having evidence of compensated or 
overcompensated DIC.
Several studies have demonstrated subclinical 
abnormalities of haemostasis in cancer patients (Sun et 
al, 1979; Doni et al, 1984) . In their series of 108 
patients, Sun et al (1979) showed that 98% of their 
patients had one or more abnormal coagulation test. The 
abnormalities commonly seen were thrombocytosis (57%), 
hyperfibrinogenemia (46%) , increased fibrin degradation 
products (68%) and thrombocytopenia (11%), clearly
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illustrating that subclinical coagulopathy is frequently 
present in cancer patients.
Plasma Fibrinopeptide A (FpA) is a sensitive 
indicator of activation of coagulation. It is found to 
be elevated in many cancer patients and has been shown 
to correlate closely with disease stage and prognosis 
(Peuscher et al, 1980; Myers et al, 1981; Mombelli et 
al, 1982) . Rickies et al, (1983) demonstrated that 
terminally ill patients show a persistently high level 
of FpA.
Various other coagulation abnormalities are seen in 
cancer patients. 1/3 of patients show decreased plasma 
Antithrombin III levels (Kies et al, 1980). This 
however, has not been corroborated in other studies 
(Miller et al, 1967; Rubin et al, 1980). Deficiencies of 
the coagulation factors II, VII, IX, X and XIII have 
also been demonstrated in patients with malignant 
disease (Miller et al, 1967).
Animal experimental work has shown altered 
coagulation in different tumour-bearing models. These 
include thrombocytopenia, hyperfibrinogenemia, an 
increase in fibrin degradation products, decreased 
fibrinolytic activity, leucocytosis and microangiopathic 
haemolytic anaemia (Hilgard et al, 1973; Rasche, 1974; 
Poggi et al, 1977; Hilgard, 1977; Chmielewska et al,
1980). Using thromboelastography, Raina et al (1985) 
showed significant acceleration of coagulation in 
tumour-bearing animals in an experimental model. They 
further observed, that complete resection of the tumour
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restored coagulation to normal while partial resection 
or sham operation did not.
3.2 The role of fibrin and the fibrinolytic system in 
malignant disease.
Fibrin has been frequently demonstrated within and 
surrounding neoplasms. This was first demonstrated in 
transplanted tumours (Day et al, 1959) and was further 
confirmed in human tumours (O'Meara & Jackson, 1958; 
Hiramoto et al, 1960; Dvorak et al, 1981). The presence 
of fibrin in malignant tumours has attracted 
considerable attention and the relevance of it's 
presence has been subject to several interpretations, 
some of which are speculative with very little direct 
support. It has been believed to be a source of 
nutrition (Ambrus et al, 1982), a preventive barrier for 
the spread of tumour cells and a source of "angiogenesis 
factors" to facilitate the growth of blood vessels into 
the tumour (Dvorak et al, 197 9). Fibrin is an early and 
consistent marker of tumour cell stroma. It is deposited 
within hours of tumour implantation and remains in the 
tumour throughout the period of tumour growth (Dvorak et 
al, 1984) . It appears to have opposing effects in the 
development of metastasis. At the level of the primary 
neoplasm, fibrin may play a dual role in tumour growth 
and spread by a) promoting primary tumour growth and b) 
preventing cell shedding by forming a barrier.
There is considerable evidence that neoplastic cells 
secrete plasminogen activators at a higher rate and in
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different ways from normal cells (Markus et al, 1983; 
Skriver et al, 1984). Some workers have suggested that 
this increased plasminogen activator (PA) production may 
be an essential step in the metastatic process though 
others have shown no correlation between PA production 
by tumour cells and metastatic potential (Wang et al, 
1980; Whur et al, 1982; Eisenbach et al, 1985) . An 
important study by Ossowski and Reich (1983) showed that 
injection of specific antibodies to human PA into a 
chick embryo significantly reduced the number of 
metastases arising from a transplanted primary tumour of 
human origin. In further animal experiments they showed 
that inhibition of the PA pathway by a polyclonal 
antibody drastically reduced the metastatic potential of 
various human tumour cell lines (Ossowski, 1988). On 
balance, the evidence suggests that PA by generating 
local proteolytic activity enables tumour cells to 
overcome the natural barrier of the vascular basement 
membrane permitting them to enter the circulation (Dano 
et al, 1985; Liotta, 1986).
Circulating tumour cells may form aggregates with 
platelets and fibrin which facilitate their trapping 
within the microcirculation of target organs, thereby 
enhancing their metastatic efficiency (Crissman, 1984). 
The earlier view that fibrin destroys trapped tumour 
cells (Iwasaki, 1915), has now been abandoned. Contrary 
to this view, the current belief is that fibrin may 
facilitate adhesion of tumour cells to vascular
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endothelium by acting as an intercellular "glue" 
(Francis, 1989) .
When it was realized that fibrin may be involved in 
tumour growth and spread, several workers began 
investigating the effect of fibrinolytic modulation in 
experimental animal tumour models. The results were 
however conflicting (Grossi et al, 1961; Cliffton & 
Agostino, 1962; Tanaka et al, 1977; Giraldi et al, 1977; 
Turner & Weiss, 1981).
In summary, the results of all these studies would 
suggest that fibrin may have several roles to play (some 
of them opposing), in tumour growth and progression:
1. To encourage local tumour growth by facilitating 
angiogenesis and perhaps serving as a nutritional 
source.
2. To form an effective barrier to tumour invasion of 
the vascular basement membrane.
3. To form a mesh with platelets to facilitate trapping 
of cells in the microcirculation of target organs 
encouraging tumour cell adhesion to vascular basement 
membrane, thereby facilitating the metastatic process.
The relative importance of these various actions 
under clinical conditions is unknown at present.
3.3 The role of platelets in malignant disease:
Platelets appear to be closely associated with the 
development of malignant disease. 30-60% of cancer 
patients have thrombocytosis (Sun et al, 1979; Rickies & 
Edwards, 1983b) and 4-11% have thrombocytopenia
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(Hagedorn et al, 1974; Sun et al, 1979). The aggregation 
of platelets around tumour cells was first described in 
1903 (Schmidt) . This was confirmed by Wood et al (1958; 
1961) in their classic cinemicrographic studies of the 
fate of injected tumour cells in the blood stream. In 
their experiments, they demonstrated an association 
between platelet thrombus formation and tumour cell 
deposition. Platelet-tumour cell emboli have often been 
proposed to facilitate the entrapment of tumour cells in 
the microcirculation (Jones et al, 1971). Crissman et al 
however suggest that tumour cell-induced platelet 
aggregation occurs after the initial arrest has occurred 
(Crissman et al, 1985). Electron microscopy has 
demonstrated a massive aggregation of platelets at the 
site of tumour emboli after the initial arrest of 
intravenously injected tumour cells. Platelet 
disaggregation commences after 3 hours and tumour cells 
attach themselves to the vascular endothelium by short 
pseudopodia (Sindelar et al, 1975). It would seem that 
one of the ways platelets function in the metastatic 
process is by stabilising the initial adhesion between 
tumour cells and endothelium. Gasic et al (1973) studied 
platelet-tumour cell interactions in mice and showed 
that tumour cell lines produced platelet aggregation 
both in vitro and in vivo. They also demonstrated the 
presence of membrane associated platelet-aggregating 
material in these tumours (Gasic et al, 1973). 
Subsequent studies demonstrated that platelet- 
aggregating material of cultured murine tumours is
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spontaneously shed in the form of membrane vesicles 
(Pearlstein et al, 1979). This platelet-aggregating 
material contains sialic acid and requires complement 
for it's activation. It is inhibited by trypsin, 
adenosine, indomethacin, phospholipase and cyclic AMP 
(Pearlstein et al, 1980; Hara et al, 1980(b); Karpatkin 
& Pearlstein, 1981; Bastida & Ordinas, 1988; Cavanaugh 
et al, 1988). Adhesion of the tumour cell-platelet 
aggregate to disrupted vascular endothelium leads to the 
formation of a dense fibrin layer and firm adhesion to 
the subendothelial layers.
Several in vitro studies have shown that platelets 
contain a growth-promoting factor for tumour cells 
(Kohler & Lipton, 1977; Eastment & Sibrasku, 1978; Hara 
et al, 1980) . Cowan & Graham (1981) demonstrated that 48 
different tumours grown in culture were stimulated by 
platelet-derived factor. The significance of this 
remains unclear since platelet-derived growth factor may 
may stimulate normal fibroblasts, smooth muscle cells 
and glial cells in vitro (Kohler & Lipton, 1974; Ross et 
al, 1974; Westermark & Wasteson, 1976). In addition, it 
has been postulated that platelets enhance tumour cell 
adhesion to extracellular matrix via specific platelet 
glycoprotein receptors, lb and the Ilb/IIIa complex 
which interact with both tumour cells and the 
subendothelial matrix (Grossi et al, 1987). Finally, 
implantation of tumour cells may be encouraged by 
platelet-derived vascular permeability activity (Donati 
& Poggi, 1980).
49
Based on the evidence presented above, various 
antiplatelet agents have been used in animal tumour 
systems to prevent metastatic disease. The results of 
these studies have not been consistent (Wood & Hilgard, 
1972; Gasic et al, 1973; Gordon et al, 1979, Zacharski 
et al, 1982) .
Therefore it appears that platelets play an 
important role in malignant disease. Tumour cells are 
capable of aggregating and activating host platelets 
thereby promoting metastasis. In animal experiments, 
platelet-aggregating activity correlates well with the 
metastatic potential of tumour cells. Tumour cell 
survival may be enhanced by platelet-derived growth 
factors. Platelets may encourage tumour cell adhesion to 
the extracellular matrix. The full significance of all 
these findings is as yet unclear.
3.4 Procoagulant activity of tumour cells.
Tumour procoagulant activity can be detected in 
centrifuged cell-free supernatants or cell-free ascitic 
fluid from various tumour cell lines (Dvorak et al, 
1983a). Tumour cell procoagulant can be further 
categorised into three subgroups:
1. Tissue-Factor-like procoagulants
2. Factor X activators
3. Miscellaneous procoagulants
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1.Tissue factor activity in cancer cells:
Tissue Factor was first identified in 1973 by Gralnick 
and Abrell from buffy coat cells in patients with acute 
progranulocytic leukemia and is considered to be the 
main cause of intravascular coagulation seen in this 
condition. Since then, it has been identified in a 
variety of malignant tumours including lymphomas, 
adenocarcinomas and other leukemias (Sakuragawa et al, 
1977; Mussoni et al, 1986; Zacharski et al, 1986). It 
should be noted that tumour cells shed plasma membrane 
vesicles containing procoagulant activity (Dvorak et al, 
1983a). Mononuclear cells are a further source of 
procoagulant in both normal patients and patients with 
malignant disease (Edwards et al, 1981; Schwartz & 
Edgington, 1981; Semararo, 1988), although monocytes 
from cancer-bearing animals exhibit more tissue factor 
activity than monocytes from controls (Lorenzet et al, 
1983). Tissue factor activates the extrinsic pathway of 
the coagulation cascade by increasing the activity of 
Factor Vila which in turn catalyzes the conversion of 
Factor X to Xa (Dvorak et al, 1983a).
2. Factor X-activating activity
Gordon et al (1975) compared the procoagulant activities 
of normal and malignant tissues and showed that tumours, 
in addition to exhibiting tissue factor, also contained 
a procoagulant, which unlike tissue factor, did not 
require factor VII for it’s activity. This substance 
termed "Cancer Procoagulant” has the capacity to
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activate factor X directly. Gilbert and Gordon (1983) 
demonstrated a strong positive correlation between the 
metastatic potential of B16 mouse melanoma variants and 
cancer procoagulant. Similar cancer procoagulant 
activity has been shown to occur in cells from different 
experimental tumours (Curatolo et al, 1979; Hilgard & 
Whur 1980) . Procoagulant activity in benign melanocytic 
lesions is dependent on Factor VII and can be blocked by 
concanavalin A, a tissue factor inhibitor. In contrast 
to this, extracts as well as isolated cells from 
malignant melanoma lesions exhibit procoagulant activity 
which is Factor VII independent and is inhibited by 
cysteine protease antagonists but not by concanavalin A 
(Gordon et al, 1979; Donati et al, 1986). These findings 
would suggest that normal tissue contains tissue factor 
and that malignant transformation is responsible for 
cancer procoagulant production.
3. Miscellaneous procoagulants:
In addition to tissue factor and factor X-activators, 
other tumour-associated procoagulants have been 
described though they have not been confirmed (Lawrence 
et al, 1952; Boggust et al, 1963; Svanberg, 1975).
Finally, patients with metastatic disease show low 
levels of Antithrombin III and Protein C, the two major 
natural anticoagulants produced by the liver (Rubin et 
al, 1980; Honegger et al, 1981; Rodeghiero et al, 1984).
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3.5 Summary of evidence and hypothesis.
The foregoing evidence indicates the presence of complex 
interactions between haemostasis and cancer. In 
summarizing the salient points, we are especially 
interested in features of this relationship which may 
suggest ways of exploiting or inhibiting relationships 
described, so as to interfere with pathophysiology in 
ways which may have clinical potential.
To summarize:
1. Influences of cancer on the haemostatic system:
It is evident from clinical and animal studies that 
cancer activates the coagulation system. Activation of 
platelets have also been demonstrated. The effects of 
cancer on haemostasis correlate with disease progression 
and this influence may partly contribute to developing 
pathophysiology, although this is not proven. Finally, 
tumour cells have been shown to have relevant 
stimulatory effects on platelets, the coagulation system 
and fibrinolysis.
2. Influences of the haemostatic system on coagulation: 
Several theories have been offered for the presence of 
fibrin within and surrounding primary neoplasms. These 
are mainly speculative and lack supportive evidence. 
Evidence for platelets and fibrin deposits around tumour 
cells in the microcirculation is more convincing. It 
impicates fibrin and platelets in the "intravascular" 
phase of the metastatic process. Furthermore, evidence
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that plasminogen activator generates local proteolytic 
activity to enable tumour cells overcome the natural 
barrier of the basement membrane permitting them to 
enter the circulation, supports the hypothesis that 
fibrinolysis contributes to the metastatic process.
3. Haemostasis and metastasis:
The most convincing and potentially relevant area of 
evidence is that fibrin and platelets play a role in the 
"intravascular" phase of the metastatic process. 
Manipulation of the haemostatic system in animal studies 
have shown an alteration in the pattern of metastatic 
development. Anticoagulant therapy has been successful 
in inhibiting cancer metastasis in several animal 
studies and in a small number of clinical studies as 
well. It has been suggested that coumarin anticoagulants 
inhibit metastasis by virtue of their anticoagulation 
properties (Agostino et al, 1966; Ryan et al, 1969) . 
These workers showed that it was possible to achieve a 
dramatic reduction in pulmonary seeding of intravenously 
injected tumour cells by pretreating the animals with 
anticoagulants. Wood in 1974 reported that such tumour 
cells often became surrounded by a mass of adherent 
fibrin and platelets when they lodged on the vascular 
endothelium and that this phenomenon was abolished by 
anticoagulant therapy. The hypothesis that developed as 
a result of these studies is that anticoagulants inhibit 
metastasis by interfering with clot formation around
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intravascular tumour cells thereby preventing tumour 
cell adhesion to the vessel wall (Brown, 1973) .
Retrospective clinical studies have suggested that 
there might be a beneficial effect on survival in 
patients on warfarin who develop cancer. However, the 
number of cases reported is small and further 
confirmatory work is required before any conclusions can 
be drawn (Forman, 1979; Michaels, 1974; Annegers & 
Zacharski, 1980). The well conducted prospective 
randomised study by Zacharski and colleagues in the 
Veterans Administration hospitals of the USA (Zacharski 
et al, 1979; 1984) showed no detectable benefit of
anticoagulation for any category of cancer patient apart 
from small cell lung cancer. In this sub-group of 
patients, survival in the warfarin-treated group was 
approximately double that in the group that did not 
receive treatment with warfarin. The main criticism of 
this trial is that the patients admitted into it were 
mostly suffering from advanced disease and as such were 
unlikely to benefit from antimetastatic therapy which 
essentially ought to be beneficial in patients whose 
disease has not yet metastasised widely.
McCulloch & George (1987), showed that warfarin 
inhibits metastasis, whilst injection of the warfarin- 
dependent coagulation factors II, IX, X enhance 
metastasis in an animal model. Injection of factor VII 
alone (also warfarin-dependent) had no effect on tumour 
metastasis. Important areas of doubt remain as to the 
exact mechanism(s) by which coagulation factors II, IX,
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X produce tumour enhancement. These must be eliminated 
if further studies are to go from this model to 
potential clinical level.
The aim of this study was to investigate this 
phenomenon of tumour enhancement, in a similar animal 
model. In order to identify the mechanism(s) involved, 
we set out to investigate the following possibilities:
1. The observed effect of tumour enhancement by the
human coagulation factor complex II, IX, X in this 
animal model, may be directly related to it's xenogeneic 
properties. It is proposed that a comparison of the
prometastatic effects of human and rat coagulation 
factor complexes II, IX, X be made.
2. It is not unreasonable to assume that in order to 
enhance pulmonary tumour seeding, the coagulation factor 
complex II, IX, X, may be responsible for an increase in 
the number of tumour cells physically trapped in the
pulmonary microcirculation. This would theoretically 
increase the number of potentially metastatic cells in 
the lung, increasing the likelihood of a greater number 
of metastases thereby developing. It would be possible 
to detect the number of tumour cells trapped in the
pulmonary microvasculature by studying the passage of 
intravenously injected radiolabelled tumour cells, 
through the lung.
3. The role of individual factors II, IX and X on tumour 
enhancement needs to be investigated. These factors are 
closely linked to each other in the coagulation cascade
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and it is possible that any one of them might be solely 
responsible for the effect of tumour enhancement.
4. Administration of exogenous coagulation factor 
complex II, IX, X may cause activation of the 
coagulation system, resulting in the formation of 
intravascular fibrin clots. These microvascular fibrin 
clots may encourage entrapment of tumour cells, thereby 
enhancing metastasis. In order to investigate this 
possibility, highly sensitive tests of activation of 
coagulation need to be employed. It is believed that 
estimation of plasma FpA is the most sensitive indicator 
of activation of coagulation.
Furthermore, it would be interesting to investigate 
whether destruction of fibrin by fibrinolytic therapy 
has any effect on tumour metastasis.
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CHAPTER 1
VALIDATION OF PREVIOUS WORK AND THE ANIMAL MODEL OF 
METASTATIC CARCINOMA.
INTRODUCTION
The foregoing review has outlined persuasive evidence 
that malignancy affects the coagulation system in a 
diverse and profound manner. Clinical and animal 
experimental evidence has been outlined suggesting a 
beneficial effect of anticoagulation on the metastatic 
process. McCulloch and George (1987), have shown that 
Warfarin inhibits and the Warfarin-dependent factor 
complex II, IX, X enhances pulmonary tumour seeding in 
their animal model. In order to investigate this 
phenomenon of tumour enhancement by the coagulation 
factor complex II, IX, X, it was initially necessary to 
validate the results of previous workers. The most 
obvious and simple way of doing this is by adaptation of 
the existing animal model. This has the twin advantages 
of comparibility and elimination of extraneous 
variables.
Areas requiring validation:
1. Tumour model and the method of detection of pulmonary 
metastases because of the possibility of a phenotypic 
drift in the tumour cell line resulting in a possible 
change in the nature of the lung deposits.
2. Use of human coagulation factor complex II, IX, X 
because of the limited nature of the previous work: the
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results related to the dose and timing of administration 
of the factor complex are unknown.
3. Direct effect of the factor complex preparation on 
tumour cell aggregation because this may affect 
metastasis and has not been previously considered.
The original reasons for selecting this tumour model 
still apply. These are outlined below:
The tumour-host system selected requires the following 
important properties in order to represent the situation 
in human cancer as closely as possible:
a. The tumour should metastasise reliably and 
spontaneously from the primary site.
b. It should resemble human carcinoma as closely as 
possible in terms of it's histological origin, 
morphology and behaviour.
c. It should be possible to grow the tumour cells in 
vitro.
d. The tumour should be syngeneic with the host animal 
and should not elicit a significant immune response in 
the host.
e. It should be possible to effectively evaluate changes 
in the haemostatic system in the host animal.
f. Administration of intravenous tumour cells should 
give measurable and reproducible results.
The rat mammary carcinoma cell line used was the 
Mtln3  clone of the 137 62 NF mammary carcinoma. It has a 
high rate of spontaneous metastasis to the lung and 
resembles human breast cancer both morphologically and
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Figure 3 Morphology of Mtln^ rat mammary carcinoma 
cells in culture - x 625 magnification.
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in it's propensity to metastasise to regional lymph 
nodes (Neri et al, 1982) . The tumour cells have been 
shown to be syngeneic with the Fischer 344 rat, in which 
the parent tumour was raised and do not elicit a 
significant cellular or humoural immune response during 
prolonged growth in this host (North & Nicolson, 1985). 
The cloned line can be easily maintained in culture, 
though repeated passage must be avoided in order to 
retain it's metastatic potential (Neri & Nicolson,
1981) .
Metastatic tumour model.
Animals:
The animals used throughout this study were female 
Fischer 344 (F344) inbred rats (Olac Ltd, Bicester,
England). Animals were housed 3 to a cage and were fed a 
standard laboratory diet (CRM diet, Labsure, Cambridge, 
England), and tap water with a chlorine content of 7 
mg/1. No measures were taken to avoid coprophagy. All 
animals used in these experiments were normal and 
healthy according to visual observations and to the 
results of routine microbiological testing for 
infection. The mean weight of the animals at the time of 
use was 140g.
Tumour cells:
The tumour cells used in these studies were a clone of 
rat mammary carcinoma designated Mtln3  (Figure 3), 
originally derived from the 7,12-dimethylbenz (a)
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anthracene-induced adenocarcinoma 137 62 (Segaloff, 
1966) . This clone was derived from the parent tumour by 
Neri and Nicolson (Neri et al, 1982), and was 
characterized as being of high metastatic potential. 
Frozen cultures of these cells were used to establish 
the cell line in vitro at the Department of Oncology,
9University of Glasgow. Cells were cultured m  75 cm^ 
tissue culture flasks (Gibco, Paisley, Scotland), in 
equal parts of Hams' F10 and Dulbecco's Modified Eagle's 
Medium (F10/DMEM), with 10% foetal calf serum (FCS) but 
without antibiotics. Cultures were maintained at 37°C in 
equilibrium with 2% CO2 in air. Cultures were passaged 
when they approached confluence by using Ca++ and Mg++ 
free phosphate buffered saline followed by 0.25% Trypsin 
(Gibco, Paisley, Scotland). Cells were passaged a 
maximum of six times between thawing and use, to 
minimise the problems of phenotypic drift (Neri & 
Nicolson, 1981). Cultures were regularly tested for 
contamination with Mycoplasma, using Hoechst stain 
33258.
For the purpose of inoculation, the tumour cells 
were trypsinised, washed three times in F10/DMEM by 
centrifugation at 200g for 5 minutes, and finally 
resuspended in F10/DMEM. Cells were then counted using a 
Coulter model ZM counter(Coulter Ltd, Luton, England). A 
standard suspension containing 10^ cells per 0.5ml was 
prepared. Animals were inoculated with this tumour cell 
suspension by the intravenous route.
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The method selected for the detection of pulmonary 
metastases in our studies relies on the formation of 
easily detectable, discrete tumour nodules, on the 
pleural surface of the lungs.
Validation of Method for Identifying Lung Metastases
Estimation of pulmonary tumour seeding by serial 
histological section is prohibitively time consuming for 
repeated use. For studies of metastasis which would 
necessarily involve the use of large numbers of 
experimental animals, a rapid and reliable alternative 
method is required. A simple method which has proved 
reliable in other tumour/host studies, is that described 
by Wexler (Wexler, 1966). This technique is well 
validated and involves inflating the lungs via the 
trachea with a 15% solution of Indian Ink in distilled 
water, excising them and bleaching them for 48 hours in 
Fekete's solution, a bleaching fixative containing 
alcohol, acetic acid and formaldehyde. This reveals 
surface pulmonary metastases as white nodules against a 
black background (Figure 4) . Conventional histology was 
used to assess the accuracy of this method in detecting 
tumour deposits (Figures 5 a & b).
A pilot study was performed to validate:
a. the dose of Mtln^ cells previously used (10^ )
b. the optimum time of sacrifice (17 days)
c. Wexlerfs method
(McCulloch & George, 1987).
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Figure 4 Rat lungs with multiple subpleural deposits 
prepared by the method of Wexler
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Figure 5(a) Histology of pulmonary tumour deposit: 
Peribronchial tumour deposit - x 62.5 magnification
Figure 5(b) Histology of pulmonary tumour deposit: 
Tumour underlying bronchial epithelium - x 
magnification
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EXPERIMENT:
12 female Fischer 344 rats, 6-8 weeks old were given 
intravenous injections of 104 Mtln3  rat mammary 
carcinoma cells suspended in 0.5 mis of F10/DMEM, under 
chloral hydrate anaesthesia. The animals were sacrificed 
at 17 days afer injection and in 6 animals, pulmonary 
tumour nodules were assessed by the method of Wexler as 
described above. In the remaining 6 animals, the lungs 
were excised, and stored in 10% formalin/saline solution 
and subjected to serial sectioning with conventional 
haematoxylin and eosin staining. Full autopsy was 
carried out on all animals and samples of any tissue 
suspected of containing metastases were submitted for 
histological examination.
RESULTS:
Table 4 shows the number of pulmonary tumour nodules 
detected by the two methods. There was no statistical 
difference in the estimated number of tumour nodules 
detected by the two methods used and the inter-animal 
variation was very similar in the two groups (Mann- 
Whitney, p = 0.5752). No tumour deposits were seen in 
any of the other organs submitted for histology.
DISCUSSION:
This preliminary study, confirmed that the tumour model 
chosen was suitable for our purpose, namely to 
investigate influences on metastasis in an animal model. 
The tumour seeded readily and in a discrete manner in
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the lungs, following intravenous injection of a small 
dose of tumour cells. The likelihood of a major 
disturbance of the circulatory or coagulation systems, 
occurring as a consequence of injection of these cells 
is remote. The method proposed for the identification of 
pulmonary tumour nodules was also successfully 
validated. Previous work in 8 other model syestems 
(Wexler, 1966) has shown that excellent correlation 
exists between the number of surface tumour nodules 
detected by this method and the total lung tumour burden 
estimated by more rigorous but laborious methods. A 
discrepancy between the true and estimated numbers of 
pulmonary tumour nodules may arise in three ways: 
tumours may grow in a fashion which prevents accurate 
identification and counting; there may be a variable 
relationship between the total lung tumour burden and 
the surface tumour nodules; artefacts may arise which 
indicate the presence of a tumour deposit where none 
exists. The first two of these possibilities may be 
discounted in the experiments described above, where the 
pattern of tumour growth was observed. The tumour 
nodules formed were well-circumscribed and discrete and 
easily identifiable. Also, the proportion of deposits on 
the pleural surface was consistent as judged by 
histological studies and artefact formation did not 
appear to be a source of serious error when Wexlerfs 
method was applied to this tumour/host system. Direct 
comparison was made in these studies between 
quantitative estimates of tumour burden based on
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histology and those obtained using Wexlerfs method. The 
results of these studies indicate that Wexlerfs method 
of identifying surface pulmonary tumours is adequate for 
estimation of major changes in the lung burden of Mtln^ 
tumour with various treatments.
Human Coagulation Factor Complex II, IX, X.
A heat treated concentrate of human coagulation factor 
complex II, IX, X, prepared from pooled plasma by 
cryoprecipitation and supernatant adsorption with DEAE 
cellulose, was obtained from Dr RJ Perry of the Protein 
Fractionation Centre, Edinburgh, UK.
Previous experiments have shown that a dose of six 
units of prothrombin and factor X, and seven units of 
factor IX reconstitutes coagulation in a fully 
warfarinised rat for approximately 12 hours. This is the 
dose of Factor Complex that has previously been used in 
the studies wherein the effect of enhancement of tumour 
metastasis has been demonstrated (McCulloch & George, 
1987).
Studies to validate previous work.
EXPERIMENT 1.
Pilot studies to verify the enhancing effect of human 
coagulation factors II, IX, X on pulmonary tumour 
seeding. These studies also assessed whether this effect 
of tumour enhancement is dependent on the concentration 
or time of administration of the factor complex II, IX, 
X.
70
Seven groups of 4 female Fischer 344 rats each, 6-8 
weeks old were used. All animals were injected 
intravenously with 10^ Mtln^ cells as described above. 
Additional treatments were then commenced as follows:
Group A: These control animals received no additional 
treatment.
Group B: These animals received one injection of Factor 
Complex II, IX, X (6:7:6 Units), at the same 
time as tumour cell injection (t=0)
Group C: These animals received one injection of Factor 
Complex II, IX, X (1/2 of the dose administered 
in Group B animals) (t=0)
Group D: These animals received one injection of Factor 
Complex II, IX, X (1/10 the dose administered 
in Group B animals) (t=0)
Group E: These animals received one injection of Factor 
Complex II, IX, X (6:7:6 Units) (t=2hrs)
Group F: These animals received one injection of Factor 
Complex II, IX, X (6:7:6 Units) (t=4 hrs)
Group G: These animals received one injection of Factor 
Complex II, IX, X (6:7:6 Units) (t=6 hrs)
Animals were sacrificed at 17 days and pulmonary 
seeding assessed by the method of Wexler as previously 
described.
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RESULTS:
The dose and time of administration of the Factor 
Complex II, IX, X used in earlier experiments was 
validated since either a 50 % reduction in the dose or a 
2 hour delay in the time of administration eliminated 
the marked enhancing effect on pulmonary tumour seeding 
seen with the "standard" timing and dosage (Figure 6) 
(Groups B vs C, p=0.03; Groups B vs E, p=0.03, Mann- 
Whitney, Bonferoni correction for multiple comparisons).
EXPERIMENT 2.
Pilot study to determine the effect of Factor Complex 
II, IX, X on aggregability of Mtln3 tumour cells in 
vitro.
Mtln^ cells were grown in culture as described 
above, trypsinised, washed and resuspended in F10/DMEM 
without FCS at a concentration of 10^ cells/ml. Five 
such suspensions of cells were stirred very gently and 
to four of them, Factor Complex II, IX, X (6:7:6 
Units/10^ cells) was added, the fifth cell suspension 
acting as a control. For 4 hours thereafter, the cell 
suspensions were gently stirred. At several intervals 
(0, 1/2, 1, 2 and 4 hours) multiple samples of cell
suspensions were assessed for viability and cell 
aggregagation using a haemocytometer and trypan blue 
exclusion.
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RESULTS:
Aggregates of cells were monitored (Table 5) depending 
on whether the majority of cells seen, occurred singly 
(1) , or were seen in aggregates of two (2), three (3) or 
four (4) . Aggregability of Mtln3  cells remained 
unaltered when Factor Complex II, IX, X was added to
cell suspensions. Viability of cells gradually declined 
at an equal rate over a period of 4 hours in both 
experimental and control groups.
DISCUSSION:
The aim of this study was to validate the work performed 
by previous investigators, wherein the effect of tumour 
enhancement by factor complex II, IX, X, has been
demonstrated. As a result of our studies we established 
the following:
1. Human Coagulation Factor Complex II, IX, X, in a dose 
of 6:7:6 units respectively, administered as a single
bolus injection intravenously, enhances pulmonary tumour
seeding in this animal model.
2. The dose used is near to the lowest practicable, as a 
50% reduction in dosage eliminates the tumour enhancing 
effect.
3. Similarly, a delay of 2 hours or more in the time of 
administration of the factor complex relative to 
inoculation of the tumour cells eliminates this effect.
4. Factor Complex II, IX, X does not affect the 
aggregability of Mtln3  cells.
A 
Control - Tumour Cells 
B-E 
Cells + 
Factor Com
plex
a 
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In order to ensure consistency in our work, for the 
purposes of all our principal experiments, the dose of 
factor complex II, IX, X used was 6:7:6 units and this 
was administered as a single intravenous bolus, at the 
same time as tumour cell inoculation. This animal model 
was considered suitable for the purposes of our study on 
the basis of these experiments.
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Chapter 2
STUDIES TO DETERMINE WHETHER THE XENOGENEIC NATURE OF 
THE FACTOR COMPLEX IS RESPONSIBLE FOR THIS EFFECT OF 
TUMOUR ENHANCEMENT.
INTRODUCTION:
The results of the work performed thus far, have
validated previous work and confirmed that the factor
complex II, IX, X, when administered intravenously at 
the same time as the tumour cells, enhanced metastasis 
in an animal model. Several questions however, remained 
unanswered. In the previous experimental work, human 
factor complex II, IX, X was administered to the 
animals. It could be argued that the effect of
metastatic enhancement thereby produced, could in some 
way be related to the xenogeneic nature of the factor 
complex used. We regarded this unlikely, in view of the 
fact that previous workers had shown that administration 
of human coagulation factor VII, did not affect 
pulmonary tumour seeding to any significant degree and 
also because control groups for foreign protein (bovine
serum albumin) were used in all the experiments 
(McCulloch & George, 1988).
Despite this, we could not entirely exclude the 
possibility, that the effect of tumour enhancement seen 
in our experiments was secondary to the xenogeneic 
nature of the factor complex preparation. It was 
therefore essential to investigate this in greater 
detail by comparing human factor complex and rat factor
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complex II, IX, X with regard to their effects on 
pulmonary tumour seeding.
Rat factor complex II, IX, X, is not available 
commercially and to our knowledge no attempt had been 
made to prepare it.
A preliminary experiment was designed to attempt to 
prepare syngeneic rat factor complex II, IX, X. The 
method adopted was a modification of the standard method 
used to prepare human factor complex II, IX, X (Ahmad et 
al, 1989).
Preparation of syngeneic rat factor complex II, IX, X
The preparation of rat factor complex II, IX, X involves 
three principal stages:
1. Method of blood collection
Female Fischer 344 rats, 10-12 weeks old were used for 
this experiment. The animals were anaesthetised by 
halothane induction and chloral hydrate administered 
intra-peritoneally. A laparotomy was then performed. The 
abdominal aorta was cannulated and the animals were 
exsanguinated. Blood was collected in plastic bottles 
containing 6% sodium citrate in a ratio of 9:1 v/v and 
protease inhibitors (1 mM benzamidine-hydrochloride 1 mM 
phenylmethylsulfonylfluoride, 2.4 uM soybean trypsin 
inhibitor and 100 uM aprotonin). Following 
centrifugation at 2100 g for 15 minutes at 4°C, fresh 
plasma was collected.
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2. Barium citrate precipitation
1 M Barium chloride was added dropwise to the plasma 
containing all the inhibitors and the mixture stirred 
slowly for 1 hour at 4°C. The precipitate was collected 
by centrifugation at 5000 g for 20 minutes at 4°C and 
the supernatant discarded. The precipitate was
resuspended in 0.1 M sodium chloride and 10 mM barium 
chloride. The washed precipitate was again collected by 
centrifugation and resuspended in 20 mM Trisphosphate 
buffer containing 1 U/ml heparin, 1 mg/ml soybean 
trypsin inhibitor and 10 mM benzamidine hydrochloride.
3. Ammonium sulphate elution
The mixture was placed in an ice bath and 2 M ammonium 
sulphate was added dropwise with continuous stirring for 
1 hour. The supernatant was recovered after
centrifugation at 10,000 g for 30 minutes. This was
dialysed overnight at 4°C against 50 volumes of 0.15 M 
sodium chloride, 10 mM sodium phosphate and 1 mM 
benzamidine.
The resulting solution was assayed for Factors II, 
IX and X (Quick's one-stage assay) and found to contain 
a concentration ranging from 140% - 1000% of these
factors. Note: 100% normal activity = [1 unit (ml
plasma) ”■*■]. The ratios of the Factors II, IX, X varied 
from 21:10:7 to 11:6:8. For the purposes of this
experiment, the batch used had a ratio of 11:6:8. Each 
rat received a dose of 1 ml of concentrate containing 11
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units of Prothrombin, 6 units of Factor IX and 8 units 
of Factor X.
Experiment to compare the effect of human and rat factor 
complexes II, IX, X on pulmonary tumour seeding:
Three groups of Fischer 344 rats, 8 per group, 6-8 weeks 
old, were used in this experiment. All animals were 
given tail vein injections of 10^ Mtln3 rat mammmary 
carcinoma cells in 0.5mls of F10/DMEM prepared and 
administered as previously described. At the same time 
additional treatments were begun as follows:
Group A: These control animals received no additional 
treatment.
Group B: These animals received one injection of rat 
factor complex II, IX, X at the same time as 
tumour cell injection (t=0).
Group C: These animals received one injection of human 
factor complex II, IX, X at t=0..
The dose of human factor complex was similar to 
that used in previous experiments (6:7:6 Units).
Animals were sacrificed at 17 days and pulmonary 
seedings assessed by the method of Wexler, as described 
previously (Chapter 1).
Comparison of the different groups was made by 
Kruskall-Wallis and Mann-Whitney tests.
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RESULTS:
The number of pulmonary metastases in animals treated 
with rat factor complex (Group B, median 233) and with 
human factor complex (Group C, median 226) was
significantly higher than that detected in the control 
group A, (median 25) (p< 0.001). There was no
significant difference between the experimental groups B 
and C (p = 0.71) (Figure 7). Rat factor complex and
human factor complex enhanced pulmonary metastases to a 
similar degree.
DISCUSSION:
In our previous studies we have demonstrated the effect 
of enhancement of pulmonary tumour metastasis by human 
factor complex II, IX, X in a rat model. It might be
argued that the injection of foreign protein 
(xenogeneic) might have been responsible for producing 
this effect. The aim of this study was to investigate 
this possibility. To achieve this, it was necessary to 
prepare rat factor complex II, IX, X from syngeneic 
animals and compare the effect of this preparation and 
human factor complex II, IX, X, on pulmonary tumour 
metastasis.
A method was devised to prepare rat factor complex 
II, IX, X which was based on the standard method of 
preparing human factor complex II, IX, X. This was 
modified to suit our requirements. Analysis of the 
resultant preparation showed it to contain factors II, 
IX, X in very high concentration. The dose of rat factor
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complex administered differed slightly from that of the 
human factor complex. This was a result of the different 
ratios of the factors II, IX, X in the final sample 
obtained (11:6:8). Our previous experiments suggested 
that a reduction in the dose of factor complex 
administered, abolished the effect of enhancement of 
metastasis. It was essential therefore to ensure that 
the dose of rat factor complex was not lower than that 
of the human factor complex. Since it was not possible 
to obtain identical doses in both the experimental 
groups receiving coagulation factor, the nearest 
corresponding dose was opted for.
Both rat factor and human factor complexes II, IX, 
X significantly enhanced pulmonary tumour metastasis. In 
particular there was no difference in the numbers of 
metastases produced between these two experimental 
groups. The conclusion that can be drawn from these 
findings is that the xenogeneic nature of the human 
factor preparation does not contribute in any 
significant way to the phenomenon of enhancement of 
tumour metastasis.
This finding, although not entirely surprising, 
strengthened our belief that the factor complex 
preparation enhanced pulmonary tumour seeding by 
activating the coagulation system. It seems unlikely 
that both these preparations of coagulation factors, 
could produce a similar effect of tumour enhancement by 
other mechanisms.
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We have so far confirmed that the factor complex 
II, IX, X enhances pulmonary tumour seeding in our 
animal model and that this effect is unrelated to the 
xenogeneic nature of the human coagulation factor 
preparation. Having established this, we hypothesised 
that this effect of enhanced pulmonary tumour seeding 
was secondary to an actual physical increase in the 
number of tumour cells trapped within the 
microcirculation. This formed our next line of 
investigation.
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CHAPTER 3
STUDIES TO DETERMINE WHETHER THE EFFECT OF TUMOUR 
ENHANCEMENT BY FACTOR COMPLEX II, IX, X IS SECONDARY TO 
INCREASED PULMONARY ENTRAPMENT OF TUMOUR CELLS
INTRODUCTION:
From the preceding chapters, it is clear that 
intravenous injection of factor complex II, IX and X 
with tumour cells enhances pulmonary tumour seeding. The 
exact mechanism by which this effect occurs is unclear. 
The greatest known barrier to tumour cells in the 
metastatic process is the intravascular phase. Changes 
in the intravascular phase are likely to be an important 
determinant of changes in metastasis. Our earlier 
experiments suggest that the metastatic enhancement seen 
in our experiments is a direct consequence of changes in 
the intravascular phase. The most plausible explanation 
for this effect of tumour enhancement is an increased 
trapping of tumour cells in the microcirculation. It was 
therefore necessary to establish whether an increase in 
physical trapping of tumour cell emboli in the pulmonary 
microcirculation actually occurred.
To investigate this phenomenon, radiolabelled 
tumour cells were injected under different conditions 
and their passage through the the lung assessed.
Radiolabelling of tumour cells:
Several conditions must be satisfied if labelled cells 
are to be used for the study of metastasis:
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(a) The radioactive label should be firmly bound to the 
cell while it is viable.
(b) On death of the cell, the label must not be re­
utilized but be rapidly excreted from the body.
(c) The label must not alter the biological behaviour of 
the tumour cell.
(d) The label must exhibit sufficient radioactivity to 
allow in vivo detection of relatively few cells.
(e) Injected tumour cells must be radiolabelled 
uniformly.
A homogenous population of Mtln3  cells grown in 
vitro, labelled with 1^^I-iodo-2f-deoxyuridine (-^^IUDR) 
and injected into Fischer rats, fulfilled the criteria 
specified above. This analogue of thymidine is 
incorporated exclusively into the DNA of proliferating 
cells and is released only after cell death. Unlike 
thymidine, ^^IUDR is hardly re-utilized (Huges et al 
1964; Commerford 1965) . After cell death, ^^IUDR is 
released into the blood stream and rapidly degraded in 
the liver. The product of degradation is largely 
excreted in the urine.
Prior to proceeding with the proposed study, it was 
necessary to establish the following:
1. The dose range within which ^^IUDR haci no effect on 
tumour cell growth in vitro.
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2. The dose of ^^IUDR that satisfied criterion (1) and 
also produced measurable radioactivity after tumour 
cells were injected into rats.
3. The capacity of ^^IUDR to affect tumorigenecity of 
tumour cells.
4. The uniformity of uptake of isotope by the cells.
To this end, the following pilot studies were 
performed to evaluate the radiotoxicity of -*-2^IUDR on 
Mtln^ mammary carcinoma cells.
1. Pilot studies to assess a suitable non-cytotoxic dose 
of 125IUDR.
(a) Clonogenic Assay.
(b) Chemosensitivity Assay (microtiter assay).
(a) Effect of ^2^IUDR on clonal growth rate (Fidler IJ, 
1970) .
16, 25cm^ flasks, each containing the same number of
cells in 5 mis of F10/DMEM were left to incubate 
overnight at 37°C in equilibrium with 2% CC>2 in air. 24 
hours later, ^2^IUDR was added to the flasks in a dose 
range of 0.001 - 5.0 microcuries/ml (0.001, 0.005, 0.01, 
0.03, 0.05, 0.07, 0.1, 0.3, 0.5, 0.7, 1.0, 2.0, 3.0,
4.0, 5.0), with one flask acting as a control. The cells 
were exposed to 12^IUDR for 24 hours. The medium was 
then removed and the cells trypsinised, washed three 
times and resuspended in 10 mis of medium/flask. The 
cells in the control group (untreated flasks), were
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counted and then diluted down to 100 cells/ml. 5 mis of 
this cell suspension (500 cells) , were plated out into 
each of 4 petri dishes. Cells from the isotope-treated 
flasks were diluted and plated out in an identical 
manner to the control flask. The petri dishes were 
incubated at 37°C in an atmosphere of 2% CO2  in air for 
10 days. The medium was then removed and the clones 
washed with PBS, fixed in methanol and stained with 
crystal violet. Colonies were then counted.
(b) Chemosensitivity (microtiter) Assay: (Plumb JA et
al, 1989).
This assay relies on the ability of live but not dead 
cells to reduce a water-soluble yellow dye, 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) to a water-insoluble purple formazan product.
Adherent cells were plated out at a concentration 
of 103 per well in 200ul of medium in 96-well microtiter 
plates (Linbro; Flow Laboratories, Irvine, Scotland) and 
allowed to attach and grow for 2 days. The medium was 
then removed from the wells and replaced with either 
200ul of fresh medium (Control) , or 200ul of medium 
containing ^33IUDR at different concentrations ranging 
from 0.001 - 3.0 uc/ml (0.001, 0.005, 0.01, 0.03, 0.05, 
0.07, 0.1, 0.5, 1.0, 3.0). Cells were incubated with
isotope for 24 hours after which the medium was replaced 
with isotope-free medium. The medium was replaced at 24 
hour intervals for a further 2 days. On day 4 following 
isotope addition, the cells were fed with 200ul of fresh
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medium containing acid buffer. MTT (50ul) in PBS was 
added to the wells and the plates incubated for a 
further 4 hours. Medium and MTT were then removed from 
the wells, and the formazan crystals were dissolved in 
200 ul of DMSO. Absorbance was recorded in an enzyme- 
linked immunosorbent assay plate reader (Model 2550 
enzyme immunoassay plate reader; Bio-Rad Laboratories 
Ltd., Watford, England), at a wavelength of 570nm. The 
first and last rows of 8 wells which contained medium 
and PBS were used to blank the plate reader.
RESULTS:
(a) Clonogenic Assay
The number of colonies seen with each dose of isotope 
are shown in Figure 8. The control group showed a mean 
of 280 colonies. In groups treated with doses of 0.07 uc 
isotope per ml of medium and above, there was clearly a 
marked reduction in the number of colonies formed, 
whereas, doses of 0.05 uc/ml of medium and below, did 
not affect clonal growth. This would suggest that doses 
of -*-25iudr greater than 0.05 uc/ml of medium, are toxic 
to cells and interferes with cell survival and growth 
while at doses less than this, cells survive and grow 
adequately to form colonies.
(b) Chemosensitivity (Microtiter Assay).
At the end of the first 24 hours, wells with isotope at 
doses greater than 0.07 uc/ml of medium, showed a
Dose 
of IUDR 
(m
icrocuries/m
l)
89
Number of colonies
ro ro co co
cn o  cn o  cn o  cn
oo oo oo o
o
bo
o
bocn
o
o
o
b
co
o
bcn
o
o
co
o
cn
o
ro
co
cn
Figure 
8 
CLONOGENIC 
ASSAY
90
Absorbance (570 nm).
oo
cn
CD
o
C
D
J3
If
o ’—io
o
c—t
0*
cn
o
CJl
o r o
corocn
*  «•
o
oo
* *  *
o
b
W  w I W U7yT I rAA
* W  V/ V/ k/ v/ w  \/A A A |A AA A
o
o
o
Figure 
9 
Results 
of M
icrotiter Assay 
- Day 
1
Dose 
of IUDR 
(m
icrocuries/m
l)
91
o
CD
3o
CD(/)
3
CDCD
3
<
CD
C
CD
C/>
ooo
Absorbance (570 nm)
CD 00
Oo3
3
0)
UAAM/WAa a
oo * **
o
b xxxxx-
V/ \A/ 
A  /V\
* *
  aqbJ7VBh
V/ 1/ \AA/AA^ TWr
■MK-
m- * 
*
* * 
**
*
*
r )©€•
Figure 
10 
Results 
of M
icrotiter Assay 
- Day 
2
92
decrease in the number of live cells as shown by 
absorbance (Figure 9). This was further confirmed at the 
end of 48 hours (Figure 10). Doses below 0.07 uc/ml, did 
not affect cell survival and proliferation. Any increase 
in the concentration of isotope above 0.07 uc/ml, 
correspondingly decreased the number of surviving cells.
Based on the above two studies, 0.05 uc/ml of 
medium was considered to be an appropriate dose of 
■^^IUDR, for the purpose of labelling Mtln^ cells.
2. Pilot study to determine dose of injected isotope 
that will produce adequate measurable lung 
radioactivity.
Mtln3 cells were grown in culture in F10/DMEM at 37°C 
with CO2 in air, in separate flasks (4), and 
radiolabelled by incubating them with ^-^IUDR, a .^ a 
dose of 0.05 uc/ml of medium for 24 hours. Serial 
samples of cell suspensions (10^ , 10^, 10^, 107) were
counted in triplicate on a gamma counter (1282 
Compugamma, LKB, Wallac, Milton Keynes, England).
RESULTS:
The background count was 40. Mean activity in the cell 
suspensions ranged from 52 cpm with 10^ cells to 35,931 
cpm with 107 cells (Table 6). We anticipated using 
radiolabelled cells to detect pulmonary seeding 
expecting to find only a small fraction of injected 
cells within the lungs after one or more hours. An
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activity which was clearly detectable above baseline 
even after 95% reduction was therefore desirable. Based 
on these criteria, in order to be able to produce
c
measurable radioactivity in the lungs, a dose of 10° 
cells radiolabelled with -^^IUDR a dose of 0.05 uc/ml 
of medium was thought to be appropriate for use in the 
main study.
3. Pilot study to assess tumorigenicity of radiolabelled 
MtlnJ cells in vivo.
For the purpose of the main study, it was essential to 
assess if tumorigenecity of the Mtln^ cells was affected 
by radiolabelling them with ^^IUDR.
The in vitro studies previously described, 
established the dose of -^^IUDR appropriate for 
labelling of Mtln3  cells under innocuous conditions. 
However, cells exposed to toxic levels of radiation may 
undergo several normal divisions before mitotic arrest. 
Therefore, the clonal growth rate may not be an absolute 
index of radiotoxicity. Obviously, a further study was 
necessary to demonstrate that similar doses of 
unlabelled and labelled Mtln3  cells would yield a 
similar number of tumours in vivo.
MATERIALS AND METHODS:
Two groups of female Fischer 344 rats, 6-8 weeks old, 
were used in this experiment. Under general anaesthesia, 
animals were given tail vein injections of Mtln3  rat
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mammary carcinoma cells suspended in 0.2 mis of F10/DMEM 
as outlined below:
Group A: These animals received one injection of 10^ 
Mtln3  cells radiolabelled with -^^IUDR (0.05 
uc/ml)
Group B: These animals received one injection of 10° 
unlabelled Mtln3  cells.
Animals were sacrificed 17 days after tumour cell 
inoculation and pulmonary tumour seeding assessed by the 
method of Wexler (Chapter 1) . Comparison of the two 
groups was made by the Mann-Whitney Test.
RESULTS:
In all previous experiments, an inoculum dose of 10^ 
cells was used. However, as shown earlier, this dose 
would have been unsuitable to ensure measurable 
radioactivity in the main experiment. Hence for the
purpose of this study a dose of 10^ Mtln3  cells was 
opted for. As expected, this produced a far greater 
number of pulmonary metastases than that seen in
previous experiments, where a lower inoculum dose was
used. In some of the lungs, in both groups, confluence
of metastases was seen. However, all metastases that 
could be identified clearly were counted. Statistically, 
there was no significant difference between the two 
groups, in the number of metastases seen, (Figure 11, p=
0.6650, Mann-Whitney).
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This showed that labelling Mtln3 cells with -^^IUDR
at a dose of 0.05 uc/ml of medium, did not affect their
capacity to produce pulmonary metastases.
4. To ensure uniform uptake of isotope by the cells, a
simple in vitro study was performed.
MATERIALS AND METHODS:
Mtln3 cells were grown in 10 separate flasks. Cells were 
incubated with ^^IUDR at a dose of 0.05 uc/ml for 24 
hours. Following trypsinisation, the labelled cells were 
washed several times to remove non-bound isotope and 
then resuspended in F10/DMEM. Different doses of 
inocula, ranging from 10^ - 10^, one dose per flask, in 
1 ml of medium, were monitored in a gamma counter and 
radioactivity measured.
RESULTS: (Table 7)
IOC
This experiment demonstrated uniform uptake of ■LAJIUDR 
by Mtln3  cells grown in culture in different flasks. It 
further confirmed that at inoculum doses below 10^ of 
cells, measurable radioactivity was too low to be 
considered for use in the proposed main experiment.
As a result of the above 4 pilot studies, the 
following criteria were established:
1. A satisfactory labelling dose of ^^IUDR that was 
non-cytotoxic to Mtln3  cells was 0.05 uc/ml of medium.
Background 
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2. The appropriate inoculum dose of cells, labelled with 
125iudr at this dose of 0.05 uc/ml of medium, that would
ftreliably produce measurable radioactivity, was 10°.
3. Radiolabelling Mtln^ cells with -^^IUDR did. not 
affect tumorigenecity in vivo.
4. Uniform uptake of the isotope by Mtln3  cells was 
noted to occur, in vitro.
Experiment to determine whether enhancement of tumour 
metastasis is due to increased pulmonary entrapment of 
tumour cells.
MATERIALS AND METHODS:
Mtln^ cells were cultured in 75cm^ tissue culture flasks 
in F10/DMEM with FCS, at 37°C, in equilibirium with CO2  
in air. When cells had reached their phase of 
exponential growth, ^^IUDR was added to the flasks at a 
dose of 0.05 uc/ml of medium. The flasks were incubated 
for a further 24 hours. Cells were then trypsinised and 
washed several times to remove unbound isotope. Cell 
suspensions were diluted to yield an inoculum dose of 
10° in 0.2 mis of F10/DMEM. Representative inoculum 
doses were monitored in a gamma counter.
Fischer 344 female rats, 6-8 weeks old, were given 
tail vein injections of 10^ radiolabelled cells, under 
general anaesthesia. At the same time, additional 
treatments were begun as follows:
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Group A: These control animals received no additional
treatment.
Group B: These animals received one injection of bovine
serum albumin (Sigma, Poole, UK), in a dose of
30 mg in 0.6 mis of F10/DMEM.
Group C: These animals received one injection of human
factor complex II, IX, X.
The origin and dosage of the factor complex used 
are described in Chapter 1. The dose of bovine serum 
albumin used was selected so as to contain the same 
protein concentration as the factor complex preparation 
in Group C rats. Both preparations were passed through a
0.2 urn filter before injection, for sterilization and 
removal of any particulate material which might embolise 
in the pulmonary microcirculation.
At the following intervals after injection, three 
animals per group were exsanguinated, their lungs 
removed immediately and placed in individual containers 
containing 70% ethanol: 5, 10, 30 minutes, 1, 6, 12 and
18 hours.
Lung radioactivity was measured in a gamma counter 
and expressed as a percentage of the total amount of 
radioactivity injected. Each sample was counted twice. 
Comparison of the three groups was made by analysis of 
variance and Student's t tests.
Hours 
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RESULTS:
In all groups, an initial peak and trough of activity 
was noted in the first 30 minutes which was followed by 
an exponential decline with time (Figure 12). At 1 hour, 
the activity in the factor-treated rats (Group C) was 
82.84% This was significantly higher than that in the
control (Group A, 62.34%) and that in rats treated with 
bovine serum albumin (Group B, 50.10%, p < 0.001 on 
analysis of variance and Student’s t tests, Figure 12). 
This significant difference persisted at all times 
thereafter. At 1 hour, but not thereafter, the
difference between Groups A and B reached statistical 
significance (p = 0.018).
DISCUSSION:
We have already established that factor complex II, IX, 
X, enhances metastasis in an animal model. We 
hypothesized that this effect was probably secondary to 
an increase in the physical trapping of tumour cell
emboli in the pulmonary microcirculation. The aim of 
this experiment was to assess this phenomenon in our
ioc
animal model using radiolabelled tumour cells. -L*'w'IUDR 
was regarded as a suitable isotope for this purpose, 
based on previous studies (Fidler, 1970), wherein the 
fate of radiolabelled tumour-cell emboli have been 
studied.
l^IUDR at a dose of 0.05 uc/ml of medium, labelled 
Mtln^ cells satisfactorily in a uniform manner, was non- 
cytotoxic, and did not affect tumorigenecity in vivo.
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Within the first 10 minutes of injection of tumour 
cells, there was a sharp rise in measured radioactivity 
in all experimental groups. This is thought to be due to 
trapping of tumour cells on first passage through the 
pulmonary circulation. In addition, some tumour cells 
that escape entrapment on first passage recirculate and 
may arrest in the pulmonary capillary bed subsequently. 
(Fidler, 1970). At the end of one hour the radioactivity 
measured in the lungs of animals administered factor 
complex II, IX, X along with tumour cells was 
significantly higher than that in the animals receiving 
cells alone or cells with bovine serum albumin, a 
difference that persisted till the end of the experiment 
at 18 hours. After one hour measured radioactivity 
showed an exponential decline with time indicating death 
of the tumour cells.
125iudr is incorporated exclusively into the DNA of 
proliferating cells, is released only on breakdown of 
cell DNA following cell death, and is hardly re-utilized 
(Huges et al, 1964; Commerford, 1965) . Therefore the 
radioactivity measured in the lungs is a direct 
indication of the number of live tumour cells trapped in 
the pulmonary microcirculation at any given time. The 
increase in measured radioactivity in the lungs of 
animals receiving factor complex II, IX, X along with 
tumour cells can be attributed to increased pulmonary 
entrapment of tumour cells. This may be a contributory 
factor in producing the effect of enhancement of 
metastasis in our animal model. The exact reason for
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this phenomenon of increased tumour cell entrapment is 
unclear. Several possibilities however exist.
Utilizing both electron microscopy and fibrin- 
specific immunofluorescence, it has been demonstrated 
that shortly after injection, tumour cells arrest in 
pulmonary capillaries and are surrounded by aggregated 
platelets and non-cross-linked fibrin (Jones et al., 
1971; Chew and Wallace, 1976; Sindelar et al., 1975). 
Maximum numbers of thrombi are seen 1-3 hours after 
injection and these progressively decrease over 18 
hours. Thrombus dissolution commences after 3 hours and 
tumour cells are then seen attaching themselves to the 
vascular endothelium. The formation of this thrombus, 
consisting of aggregated platelets and non-cross-linked 
fibrin around tumour cell emboli, is thought to 
encourage tumour cell arrest and adherence to the 
vascular endothelium. It is possible that factor complex 
II, IX, X may have an effect on platelet aggregability, 
thereby enhancing the formation of aggregates of 
platelet thrombi around tumour cell emboli. 
Alternatively, injection of this complex of factors may 
directly activate the coagulation system leading to the 
formation of a fibrin clot. Wood (1958) originally 
hypothesised that fibrin clot encourages adherence of 
tumour cells to vascular endothelium.
Whatever the mechanism involved, it is clear that a 
greater number of tumour cells are trapped in the 
pulmonary microcirculation on administration of the 
factor complex II, IX, X. We have already demonstrated
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that the xenogeneic nature of the factor complex 
preparation is not responsible for this phenomenon of 
tumour enhancement. What is unclear at this stage is 
whether any one of the three factors II, IX and X is 
solely responsible for this observed effect. This formed 
the basis of our next study.
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CHAPTER 4
STUDIES TO IDENTIFY WHICH COMPONENT OF THE FACTOR 
COMPLEX II, IX, X, IS RESPONSIBLE FOR ENHANCEMENT OF 
TUMOUR METASTASIS.
INTRODUCTION:
The results of the foregoing studies suggest that the 
enhancement of tumour metastasis seen with factor
complex II, IX, X is secondary to increased trapping of 
tumour cells in the pulmonary microcirculation, this 
effect commencing within the first hour of injection. It 
has also been shown that this effect of enhancement of 
metastasis is unrelated to the xenogeneic nature of the 
factor complex, since rat factor complex II, IX, X
produces a similar effect. It was clearly important to 
investigate which component of the factor complex II, 
IX, X was responsible for this effect of tumour
enhancement. Identification of the coagulation factor(s) 
responsible, would be a step further in contributing to 
the understanding of the complex relationship between 
this aspect of the coagulation system and tumour
metastasis. Also, should one specific factor of the 
factor complex II, IX, X be implicated, then therapeutic 
manipulation of the factor concerned in an attempt to 
reduce tumour metastasis, would be an attractive 
proposition.
Factors II, IX and X are very similar in their 
structural and chemical properties. The amino acid 
sequence around the active site in these enzymes has
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considerable homology with that of the pancreatic serine 
proteases trypsin, chymotrypsin and elastase (Davie et
al, 1979). The active site itself involves serine, 
histidine and arginine residues linked by hydrogen 
bonding, in a manner which allows the hydroxyl oxygen 
atom of the serine residue to act as a strong
nucleophile (Blow et al, 1969). The factors are normally 
present in plasma in an inactive zymogen form. Limited 
proteolysis activates the zymogen by producing a new 
carboxy terminal amino acid. This results in a 
conformational change with a great increase in enzymatic 
activity. Active sites are found in the constant carboxy 
terminal region of about 250 residues, which is common 
to all these factors. Activation does not result in
significant reduction in the size of these molecules, 
except in the case of factor II (prothrombin) , whose 
molecular weight decreases by 50 percent following
activation.
As a result of the similarity between these three 
factors, they have, until recently, been difficult to 
separate out in their purified forms.
The aim of this study was to assess what effect 
administration of purified factors II, IX and X, given 
individually and in various combinations, would have on 
pulmonary tumour seeding.
MATERIALS AND METHODS:
It was essential initially to obtain pure preparations 
of individual factors II, IX and X. These were obtained
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from Enzyme Research Laboratories, Michigan, U.S.A. 
Purification was achieved by the method of Ahmad et al 
(1989), who originally devised the method of 
successfully separating these three factors. Their 
method is briefly outlined. Initially, blood is 
collected in 3.8% sodium citrate with protease 
inhibitors. This is then centrifuged and fresh plasma 
obtained. Barium chloride is then added to the plasma 
and the factors II, IX and X are precipitated out, 
washed and resuspended in a buffer solution containing 
protease inhibitors. Ammonium sulphate is then added to 
the mixture and the supernatant recovered after 
centrifugation. This is then dialysed overnight. 
Finally, the supernatant is applied to an antibody 
affinity sepharose-gel column and the factors II, IX and 
X are separated individually. Factors II and IX were 
homogenous as judged by 10% SDS-PAGE gels and showed no 
reduction upon incubation with 2-mercaptoethanol. Factor 
X was homogenous on SDS-PAGE gels and showed total 
reduction upon incubation with 2-mercaptoethanol.
EXPERIMENT:
8 groups of female Fischer 344 rats, 4 per group, 6-8 
weeks were used in this experiment. A suspension of 
Mtln3  cells was prepared, as previously described. The 
animals were given tail vein injections of 10^ cells 
under general anaesthesia. At the same time, additional 
intravenous injections were administered as follows:
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Group A: These control animals received no additional 
treatment.
Group B: These animals received an injection of Factor
II.
Group C: These animals received an injection of Factor
IX.
Group D: These animals received an injection of Factor
X.
Group E: These animals received a combination of Factors 
II and IX.
Group F: These animals received a combination of Factors 
IX and X.
Group G: These animals received a combination of Factors 
II and X.
Group H: These animals received a combination of Factors 
II, IX and X.
The dose of the administered factors was similar to 
that used in the previous experiments (6:7:6 Units).
Animals were sacrificed 17 days after injection and 
pulmonary seedings assessed by the method of Wexler as 
previously described (Chapter 1). Comparison of the 
various groups was made by analysis of variance and 
Kruskal-Wallis tests.
RESULTS:
The number of pulmonary nodules detected in animals 
treated with factors II, IX and X, given individually
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and in various combinations (Groups B-H), was 
significantly higher than that in the control group A (p 
= 0.012) (Figure 13). The median number of metastases in 
"treated" animals ranged from 131 - 270 compared with a 
median value of 13 in untreated controls. No significant 
difference was found between the individual groups B-H 
on statistical analysis (p = 0.119). Factors II, IX and 
X administered individually and in combination enhanced 
pulmonary metastasis to a similar degree.
DISCUSSION:
The role of the factors II, IX and X in the coagulation 
pathway is depicted in figure 1 (Introduction). In the 
intrinsic system, activation of factor X by activated 
Factor IX, leads to activation of factor II to form 
thrombin. Thrombin acts on fibrinogen to form fibrin.
This experiment demonstrates the effect of factors 
II, IX and X on pulmonary tumour seeding, when 
administered individually and in various combinations. 
All three factors produce a significant enhancement of 
tumour seeding, irrespective of whether they were given 
individually or in various combinations. In particular, 
there was no difference in the numbers of metastases 
produced between the individual treatment groups, 
suggesting that the factors individually and in 
combination enhanced metastasis to a similar degree. 
This suggests that they may do so via a common pathway, 
possibly related to activation of the coagulation
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system, ultimately leading to the formation of a fibrin 
clot.
The presence of fibrin, in thrombi surrounding 
tumour cell emboli, arrested in pulmonary capillaries, 
has been discussed in Chapter 3. Some studies have 
demonstrated an association between tumour cells and 
fibrin. Sindelar and colleagues (1975) however, showed 
no evidence of fibrin deposits at the intravascular 
sites of tumour arrest. They demonstrated that platelet 
aggregates formed the thrombus which surrounds arrested 
tumour cell emboli. Chew and Wallace (197 6) emphasise 
that both non-cross-linked and cross-linked fibrin may 
be present in very small amounts and may be easily 
missed. What is not clear is whether fibrin formation 
has any effect on the process of embolization and 
subsequent growth of tumour cells. It is possible that 
fibrin, may form an amalgam with platelet aggregates and 
may aid in tumour cell arrest and adherence to vascular 
endothelium.
If fibrin does play an important role in the 
promotion of metastasis, then activation of the 
coagulation system must take place for fibrin to be 
formed. This study has shown that the factors II, IX and 
X enhance metastasis to an equal degree. It is possible 
that activation of factor II (prothrombin), via the 
intrinsic system, might be the common pathway involved. 
This would lead to an increased formation of thrombin 
and thereby fibrin. We have previously demonstrated that 
the factor complex II, IX, X, encourages trapping of
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tumour cells in the pulmonary microcirculation (Chapter 
3) . This entrapment of tumour cells may be secondary to 
activation of coagulation, resulting in the formation of 
a fibrin clot, which by encouraging lung trapping of 
tumour cells could facilitate enhancement of tumour 
seeding.
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CHAPTER 5
STUDIES TO DETERMINE WHETHER METASTATIC TUMOUR 
ENHANCEMENT OCCURS SECONDARY TO ACTIVATION OF THE
COAGULATION SYSTEM.
INTRODUCTION:
The studies performed thus far have suggested that the 
factor complex II, IX, X, enhances pulmonary tumour 
seeding by encouraging trapping of tumour cells in the 
pulmonary microcirculation. This effect of tumour 
enhancement is seen when the factors are administered 
individually or in various combinations. This has led us 
/to believe that factors II, IX and X produce this
effect of tumour enhancement by acting via a common 
pathway. It is hypothesised that the factor complex
activates the coagulation system, resulting in the 
formation of a fibrin clot. This fibrin clot would 
encourage tumour cell entrapment resulting in the 
enhancement of tumour burden previously seen in our 
experiments. This study was designed to investigate
whether administration of factor complex II, IX, X 
resulted in activation of the coagulation system.
Immunological assays for the breakdown products of 
fibrin have been available for a number of years. These 
give a rough measure of the activity of the coagulation 
system. High levels of fibrin(ogen) degradation products 
(FDP) reflect excessive activity in either the 
coagulation system or the fibrinolytic system, or both. 
These assays however, do not pin-point which system is
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activated. A more sensitive way of monitoring
haemostatic function is the measurement of specific 
products of individual reactions. Recently assays have
been established to measure specific short-lived 
reaction products of both thrombin-mediated conversion 
of fibrinogen to fibrin and plasma-mediated 
fibrinolysis. Fibrinopeptide A (FpA) is a 16 amino-acid 
peptide cleaved from the alpha chain of the fibrin
molecule in the first stage of the formation of fibrin 
(Rickies & Edwards, 1983). Elevation of plasma FpA is 
regarded to be a sensitive indicator of activation of 
the coagulation system (Introductory Chapter). Since FpA 
is excreted in the urine, urinary FpA can be measured in 
urine collected over a period of time.
Measurement of Urinary Fibrinopeptide A:
Measurement of urinary FpA seems an attractive
proposition, since in theory it gives us an overall
picture of activation of the coagulation system over a 
period of time, unlike estimation of plasma FpA which 
can only provide a "snapshot" of activity at one fixed 
time.
Preliminary experiments were performed wherein 
suprapubic catheterisation of the rat's urinary bladder 
was attempted. This resulted in significant 
contamination of the urine sample with blood. This 
method of urine sampling was regarded as being 
unsuitable for the purpose of our experiment, since any
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contamination of samples with blood will give an 
erroneously high level of FpA.
A further series of experiments were hence 
performed to ensure that bladder catheterisation per 
urethra was feasible in the rat, and that adequate 
volumes of urine were obtainable over a period of an 
hour, to facilitate FpA estimation. It was also 
important to ensure that the samples of urine were not 
contaminated with blood since this would invalidate the 
results.
Pilot study to establish method of urine collection and 
estimation of urinary FpA.
MATERIALS AND METHODS:
8 female Fischer 344 rats, 6-8 weeks old were used in 
this study. Under chloral hydrate anaesthesia animals 
were administered a thrombogenic dose of Factor Complex 
II, IX, X (200 U/Kg) , intravenously via the tail vein. 
The animals were then catheterised per urethra using a 
4FG polythene catheter (Portex Limited, Kent, UK) . To 
ensure adequate flow of urine, the animals were 
initially administered an intravenous injection of 1 ml 
of 0.9% saline to load their circulation. This was 
followed 20 minutes later by a slow intravenous 
injection of Frusemide (Hoechst UK Ltd, Hounslow, 
Middlesex), lmg/kg body weight. Urine was collected in 
plastic bottles and snap-frozen. The animals were 
sacrificed at the end of the experiment by cervical
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dislocation. Samples were sent to the Headquarters 
Laboratory, Scottish Blood Transfusion Service, 
Edinburgh, for analysis (Dr I McGregor)
The method of analysis of urinary FpA is similar to
the method used to assay rat plasma FpA (Drummond et al, 
1991) . 1/2 of each sample was diluted in assay buffer
(0.05m tris [hydroxymethyl] methylamine, 0.1% ovalbumin) 
and assayed separately.
RESULTS:
The results of this pilot study are shown in Table 8. 
Estimation of urinary FpA to assess activation of the 
coagulation system was deemed unsatisfactory for the 
following reasons:
1. All 8 samples showed microscopic contamination with 
blood, presumably traumatic in origin.
2. FpA is unstable if urine is stored at -40°C for long
periods, although addition of buffer with ovalbumin
enhanced stability.
3. Canine experiments performed simultaneously in 
Edinburgh to assess the value of estimation of urinary 
FpA showed poor correlation between plasma Fpa and 
urinary FpA over short term experiments (McGregor I,
personal communication) . This is thought to be due to
the fact that excreted intact FpA represents only 0.8%
of total generated FpA, the rest being degraded by
peptidase. Based on these results we decided to assess 
activation of the coagulation system by assaying plasma 
FpA.
m
inim
um
 
contam
ination 
m
oderate 
contam
ination 
severe 
contam
ination
118
+ + + + +
+
Table 
8 
Analysis 
of Rat Urinary 
Fibrinopeptide 
A 
(FpA)
119
Measurement of Plasma FpA:
Method of sampling plasma:
Under general anaesthesia, female Fischer rats were 
subjected to a midline laparotomy. The abdominal aorta 
was identified and cannulated. Blood was collected in 
plastic tubes containing anticoagulant solution in a 
final concentration of Heparin 1000 U/ml and Trasylol 
1000 Kallikrein Inactivator U/ml in a 0.15 molar 
solution of sodium chloride, in a ratio of 1 volume of 
anticoagulant solution to 9 volumes of blood. The 
samples were centrifuged at 2100 g for 15 minutes at 
4°C. The fresh rat plasma thus obtained was snap-frozen 
and stored at -70°C prior to analysis of FpA.
Method of analysis:
Samples of rat plasma were analysed at the National 
Science Laboratory, Scottish National Blood Transfusion 
Service, Edinburgh by a method previously reported by 
them (McLaughlin et al 1991; Drummond et al 1991).
Prior to proceeding with the main study, it was 
essential to establish whether our method of sampling 
blood was suitable for the estimation of FpA. A pilot 
study was hence performed, to assess:
a. if adequate controls could be obtained
b. if a rise in FpA could be demonstrated on 
administering a thrombogenic stimulus to the rat
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c. what would be the most suitable time of sampling 
blood after administration of a thrombogenic stimulus to 
the animal.
Pilot study to validate method of sampling of blood to 
facilitate detection of plasma FpA:
EXPERIMENT:
4 groups of female Fischer 344 rats 4 per group, 6-8 
weeks old, were used for the purpose of this experiment. 
Under general anaesthesia the following procedures were 
performed:
Group A: These animals received no treatment and had
blood sampled for estimation of FpA (Control).
Group B: These animals received an intravenous injection
of a thrombogenic dose of Factor Complex II,
IX, X (200 U/Kg) and had blood sampled at 15 
minutes after Factor Complex injection.
Group C: These animals received 200 U/Kg of Factor
Complex II, IX, X intravenously and had blood 
sampled at 30 minutes.
Group D: These animals received 200 U/Kg of Factor
Complex II, IX, X intravenously and had blood 
sampled at 60 minutes.
Samples of plasma were prepared and stored as 
described above.
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RESULTS:
This study showed that this method produced reliable 
control levels of plasma FpA (Table 9) . Secondly, a 
thrombogenic dose (200 U/Kg) of Factor Complex II, IX, X 
produced a detectable rise in plasma FpA. Finally, for 
the purpose of our experiment, a suitable time of 
sampling blood for estimation of FpA appeared to be 30 
minutes after factor complex injection.
Having established that we could reliably assay rat 
plasma for FpA, using the above method of blood 
sampling, we proceeded in our main experiment to look 
for evidence of activation of the coagulation system by 
estimating FpA under different experimental conditions.
EXPERIMENT: Study to determine whether low-dose factor
complex II, IX, X, causes activation of coagulation as 
detectable by estimation of FpA.
MATERIALS AND METHODS:
4 groups of female Fischer 344 rats, 10 per group, 6-8 
weeks old were used. Under terminal anaesthesia, the 
following procedures were carried out:
Group A: These control animals received no treatment and 
had blood samples taken for estimation of FpA. 
Group B: These animals received an intravenous injection 
of Mtln3 cells (10^ ) and had blood samples 
taken at 30 minutes after injection.
Group C: These animals received Mtln3 cells (10^ ) and
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Factor Complex II, IX, X (6:7:6 Units) 
intravenously and had blood sampled at 30 
minutes after injection.
Group D: These animals received an intravenous injection 
of Factor Complex II, IX, X (6:7:6 Units) and 
had blood sampled 30 minutes after injection.
Rat plasma was prepared and stored for analysis of 
plasma FpA as described above.
Comparison of the different groups was made using 
the Mann-Whitney test with Bonferoni correction for 
multiple comparisons.
RESULTS: (Figure 14)
The levels of FpA obtained in the control group A were 
consistent (Median = 23.20). Animals administered factor 
complex showed a significant rise in plasma FpA when 
compared with controls (Groups A Vs D, p = 0.0080) . 
Administration of tumour cells alone did not give rise 
to a significant increase in the level of FpA (Groups A 
Vs B, p= 0.22). Administration of tumour cells with 
factor complex caused a rise in detectable FpA similar 
to that seen in the group receiving factor complex alone 
(Groups A Vs C, p=0.0192; Groups B Vs C, p= 0.3691).
DISCUSSION:
This study was designed to assess whether activation of 
coagulation occurred on administration of tumour cells
G
roups
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or factor complex II, IX, X. Immunological assays for 
the breakdown products of fibrin have been available for 
years. These give a rough measure of the activity of the 
coagulation system. High levels of fibrin(ogen) 
degradation products (FDP) reflect excessive activity in 
either the coagulation system or the fibrinolytic system 
or both. These assays do not however pin-point which 
system is activated. A more sensitive method of 
monitoring haemostatic function is the measurement of 
specific products of individual reactions. Elevation of 
FpA is regarded to be a sensitive indicator of 
activation of the coagulation system. It suffers however 
from the disadvantage that it only provides a "snapshot" 
of activity at one fixed time, the time of sampling. 
Since FpA is excreted in the urine, we believed that an 
estimation of urinary FpA over a period of one hour 
would provide a more accurate assessment of the level of 
activation of the coagulation system.
The method of collection of urine suprapubically 
and per urethra suffered two main disadvantages:
1. Contamination with blood, probably traumatic in 
origin.
2. Inadequate volumes for assay despite a fluid 
challenge and diuretics.
As a result of these twin problems, this method was 
abandoned for the more feasible method of assaying 
plasma FpA.
Estimation of plasma FpA posed a few problems in 
interpretation. We were conscious that the information
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obtained from this assay only provided us with an 
indication of activity of the coagulation system at one 
fixed point in time. Our preliminary studies suggested 
that the most suitable time of sampling blood for assay 
of FpA was 30 minutes after tumour cell injection. 
Having established this, we discovered that in all our 
experiments of FpA estimation occasional values showed 
wide variation within the same group. This made the 
results slightly more difficult to interpret. By 
analysis of all the data collected however, we were able 
to define clear and consistent differences between the 
study groups.
Our results showed that factor complex administered 
either alone or along with tumour cells, caused a 
significant rise in the level of plasma FpA. We also 
noted that tumour cell administration caused a small 
rise in the level of FpA. This however did not reach 
statistical significance. The marginal rise in the level 
of FpA detected on administration of tumour cells may be 
related to the procoagulant properties that tumour cells 
possess. Previous work performed to study the 
procoagulant properties of the Mtln3  cell line has shown 
that this tumour cell line does possess a small 
procoagulant effect (Personal communication, P 
McCulloch, 1991). This would explain the marginal rise 
in FpA seen in this study.
Our studies thus far have demonstrated that in this 
animal model, coagulation factors II, IX, X when 
administered with tumour cells activate coagulation and
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encourage tumour cell entrapment within the pulmonary 
microcirculation. Our working hypothesis is that for 
this process to take place, fibrin clot formation must 
take place. The controversy surrounding the role of 
fibrin in the metastatic process has already been 
discussed (Chapter 3). Further investigation is now 
required to assess whether fibrin clot formation is 
responsible for this effect of tumour enhancement.
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CHAPTER 6. 
DOES THE EFFECT OF ENHANCEMENT OF TUMOUR METASTASIS BY 
FACTOR COMPLEX II, IX, X REQUIRE THE FORMATION OF A 
FIBRIN CLOT?
INTRODUCTION:
The studies completed thus far have identified some of 
the possible mechanisms by which Factor Complex II, IX, 
X enhances pulmonary metastasis in our tumour/host
system. Firstly, a greater number of tumour cells are 
trapped in the pulmonary microcirculation within the 
first hour of injection. During this first hour, some 
activation of the coagulation system does appear to 
occur, since there is a demonstrable rise in plasma 
Fibrinopeptide A. It seems likely that Factor Complex 
II, IX, X, when injected with tumour cells, activates
the coagulation system thereby encouraging the arrest of 
circulating tumour cells in a mesh of platelets and 
fibrin, resulting in the formation of a fibrin clot.
The hypothesis that intravascular fibrin clot 
formation contributes to the metastatic process is
controversial. We have already demonstrated that the 
effect of enhancement of tumour metastasis by Factors 
II, IX, X, in our model, may be mediated via a common 
pathway in the coagulation cascade involving the most 
distal of these factors ie. factor II (Prothrombin), 
perhaps ultimately leading to the formation of a fibrin 
clot. Using electron microscopy and fibrin-specific
immunofluorescence, previous workers have demonstrated
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the presence of tumour cells associated with platelet- 
fibrin thrombi within the pulmonary microcirculation 
within 1-3 hours of intravenous injection (Jones et al., 
1971; Chew & Wallace, 1976). Assuming the hypothesis 
that fibrin clot formation is required to facilitate 
tumour progression is correct, then treatment with
fibrinolytic enzymes or enhancement of endogenous 
fibrinolytic reactions might have a beneficial effect. 
Preliminary evidence in patients with small cell
carcinoma of the lung treated with a combination of 
chemotherapy and urokinase suggests that this might 
indeed be the case (Calvo et al, 1985) . Other workers 
investigated this possibility by administering Arvin, a 
snake venom, to animals in a similar tumour/host system 
(McCulloch & George, 1988). They found that a reduction 
in the ability of animals to form fibrin clots had no 
discernible effect on metastasis. However, it may be 
argued that the amount of fibrin required to form
metastasis is very small and in the experiments using
Arvin, complete defibrination of the animals was not 
achieved. Indeed, complete defibrination cannot be 
achieved and this has to be borne in mind when
interpreting results of defibrinating experiments. The 
alternative method of removing fibrin is to lyse fibrin 
clot once it has formed. This can be successfully 
achieved using fibrinolytic agents. An experiment was 
therefore designed to study the effect of fibrinolysis 
on pulmonary tumour seeding.
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For the purpose of our experiment, we used 
Streptokinase (Hoechst, UK) to achieve fibrinolysis. 
Streptokinase is produced by beta haemolytic 
streptococci and is antigenic and immunogenic in humans. 
This drug has been purified over the years and has been 
shown to be a valuable and effective thrombolytic agent. 
Streptokinase activates the intrinsic fibrinolytic 
system by the formation of a linkage compound between 
Streptokinase and the proactivator-plasminogen molecule. 
This complex possesses activator properties and brings 
about the conversion of plasminogen into the 
fibrinolytic enzyme plasmin. Plasminogen adsorbed on the 
clot is also activated. This results in lysis of the 
fibrin clot.
Assays to assess cytotoxicity of Streptokinase:
Prior to proceeding to study the effect of Streptokinase 
on pulmonary tumour seeding in our experimental model, 
it was essential to establish whether Streptokinase had 
any cytostatic or cytotoxic effect on the Mtln3  tumour 
cell line. Two in vitro assays were performed to look at 
this possibility:
1. Clonogenic assay
2. 4-hour Chromium release assay
1. Clonogenic assay:
Mtln3 cells were grown in culture in F10/DMEM with FCS 
in 75cm^ flasks. When confluence was attained,
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Streptokinase was added to the flasks in a range of 
different doses: 25,000, 75,000, 100,000 and 250,000
Units (4 flasks per dose) with a further fifth group 
acting as the untreated control. The cells were 
incubated for 12 hours at 37°C in equilibrium with 2% 
CO2 in air. The cells were then trypsinised, washed, and 
200 cells from each flask were plated out in petri 
dishes containing medium, and left incubated for 10
days. Colonies were then counted after staining with 
crystal violet.
2. 4-hour Chromium release assay:
Mtln^ cells were radiolabelled with Chromium^ and 
exposed to doses of Streptokinase similar to that used 
in the clonogenic assay. After 4 hours, percentage
cytotoxicity in each group was calculated using the 
formula:
C = experimental sample - spontaneous release x 100 
maximal release - spontaneous release
RESULTS:
1. Clonogenic assay:
The mean number of colonies in the experimental groups 
ranged from 142-156, with 152 colonies in the control
(Table 10) . Streptokinase did not have a cytostatic
effect on Mtln^ cells.
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Table 10
The effect of Streptokinase on Tumour Cells
Clonogenic assay
Streptokinase Dose
(Units)
0  2 5 ,0 0 0  7 5 ,0 0 0  1 0 0 ,0 0 0  2 5 0 ,0 0 0
Number of Colonies 1 5 2  14 7  156  142  137  
(C )
C: Control
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2. 4-hour Chromium release assay:
The mean percentage cell death was 2.9%. Streptokinase 
did not have a significant cytotoxic effect on Mtln3  
cells.
The results of these in vitro studies demonstrated 
that Streptokinase had no significant direct cytotoxic 
or cytostatic effect on the Mtln3  tumour cell line.
EXPERIMENT: Studies to determine the effect of
fibrinolysis on the enhanced pulmonary tumour seeding 
observed with Factor Complex II, IX, X.
8 groups of female 344 Fischer rats, 6 per group, 6-8
weeks old were used in this experiment. Under general 
anaesthesia, animals were given tail vein injections of 
a 0.5 ml suspension of 10^ Mtln3  cells in F10/DMEM. 
Additional treatment was then commenced as follows:
Group A: These animals received no additional treatment. 
Group B: These animals received an intravenous injection 
of bovine serum albumin at the same time as 
tumour cell injection (t=0).
Group C: These animals received an intravenous injection 
of Factor Complex II, IX, X at t=0.
Group D: These animals received an intravenous injection 
of Factor Complex II, IX, X at t=0 and a 
further injection of intravenous Streptokinase 
at t=15 minutes.
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Group E: These animals received the Factor Complex at 
t=0 and Streptokinase at t=30 minutes.
Group F: These animals received the Factor Complex at 
t=0 and Streptokinase at t=60 minutes.
Group G: These animals received the Factor Complex at 
t=0 and Streptokinase at t=90 minutes.
Group H: These animals received the Factor Complex at 
t=0 and Streptokinase at t=300 minutes.
The doses of coagulation factor complex II, IX, X 
and bovine serum albumin used were similar to that used 
in earlier experiments (Chapter 1) . The dose of 
Streptokinase administered was 30 000 U/Kg body weight. 
This was based on previous animal experimental work 
wherein clot lysis was achieved in vivo (Lyden et al, 
1990) . All three preparations were passed through a
0.2um filter before injection for sterilization and 
removal of particulate material that might embolise in 
the pulmonary circulation.
The laboratory tests used to monitor the animal’s 
coagulation were the thrombin time and the prothrombin 
time.
Animals were sacrificed at 17 days after injection 
and pulmonary seeding assessed by the method of Wexler 
as previously described (Chapter 1) . Comparison of the 
different groups was made by the Mann-Whitney test using 
Bonferoni’s correction for multiple comparisons.
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RESULTS: (Figure 15)
Serial measurements of the thrombin time and prothrombin 
time showed that at all time intervals ranging from 5 
minutes to 24 hours after injection of Streptokinase, 
there was no significant alteration of coagulation in 
the animals.
As expected, animals that received factor complex 
II, IX, X, along with tumour cells (Group C) , showed a 
significant enhancement of pulmonary tumour seeding 
(median = 62) when compared with control animals (Group 
A) that received tumour cells alone (median=7; p=0.025). 
Streptokinase administered 30 minutes after tumour cell 
injection returned metastases to control levels (median= 
9, p=0.025 Group C vs E) . In the remaining Groups F-H,
Streptokinase was still effective in reducing pulmonary 
tumour seeding, although when administered at 300 
minutes after tumour cell injection this effect was less 
marked (Group H, median = 19, p=0.40, group C Vs H) .
Interestingly, this effect of reduction in tumour 
seeding was not noted when Streptokinase was 
administered 15 minutes after tumour cell injection 
(Group D).
DISCUSSION:
Our earlier studies had led us to believe that the 
enhancement of tumour metastasis seen with factor 
complex II, IX, X, was secondary to increased pulmonary 
trapping of tumour cells which occurred in the first 
hour after tumour cell injection. Factors II, IX, X,
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appear to bring about this effect of tumour enhancement 
via a common pathway via factor II (Prothrombin) 
involving activation of the coagulation system. Based 
on these findings, we concluded that in order to 
facilitate enhancement of tumour metastasis the 
formation of a fibrin clot would probably be required. 
In order to investigate this possibility, the above 
experiment was designed to study the effect of 
fibrinolysis on the tumour metastasis. We worked on the 
hypothesis that if formation of a fibrin clot is 
required for the effect of enhancement of metastasis to 
take place, then fibrinolysis should reverse this 
effect.
A schematic representation of the fibrinolytic 
system is shown in Figure 2 (Introductory Chapter). The 
serine protease plasmin is essential for the dissolution 
of the fibrin thrombus. The plasma concentration of it's 
inactive precursor plasminogen, greatly exceeds the 
amount required for physiological fibrinolysis; it is 
counterbalanced by rapid inhibitors in the fibrinolytic 
system that are normally present in the circulation. 
Endogenous plasminogen is activated through the release 
of tissue-type plasminogen activator (t-PA) into the 
circulation. t-PA is constantly secreted by vascular 
endothelial cells but immediately neutralised by a 
specific inhibitor, plasminogen activator inhibitor 
(PAI-1). Under normal circumstances, any circulating 
plasmin is rapidly neutralised by alpha2-antiplasmin, a 
specific plasmin inhibitor that forms a stoichiometric
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1:1 complex with plasmin that is devoid of protease or 
esterase activity. The rate of complex formation is 
strongly dependent on the availability of free lysin- 
binding sites and a free active site in the plasmin 
molecule. Only when the circulating alpha2-antiplasmin 
level is reduced can plasmin circulate freely and exert 
a systemic proteolytic effect. Free plasmin will degrade 
not only fibrin, but also fibrinogen and plasma 
proteins, producing the so-called plasma proteolytic 
state.
Currently there are several thrombolytic agents in 
clinical use. Streptokinase and urokinase belong to the 
first generation of such agents. Produced by beta- 
haemolytic streptococci, streptokinase is antigenic and 
immunogenic in humans.
Preliminary in vitro studies showed that 
Streptokinase was not cytotoxic to the Mtln3  cell line. 
Administration of Streptokinase in vivo showed no 
significant alteration in the coagulation of the 
experimental animals. It should be remembered that 
although fibrinolytic agents ultimately prevent the 
accumulation of thrombus, they have no effect on the 
clotting process itself except at very high doses when 
breakdown products of fibrinolysis begin to interfere 
with the reactions involved. The normality of the 
coagulation tests was therefore not an unexpected 
finding but rather a reassuring indication that the dose 
used was not excessive.
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As seen in earlier experiments, factor complex II, 
IX, X, enhanced pulmonary tumour seeding. Streptokinase 
administered 15 minutes after tumour cell and factor 
complex injection did not affect this phenomenon of 
tumour enhancement. The absence of this effect in Group 
D animals can be explained by the pharmacodynamics of 
Streptokinase which has a very short circulating half- 
life (Grierson & Bjornsson, 1987). By assessing the fate 
of radiolabelled tumour cells we have previously shown 
that between 30 and 60 minutes after tumour cell 
injection, there is a sharp rise in the number of cells 
trapped within the pulmonary microcirculation (Chapter 
3) . In the experimental group D, by the time this event 
of pulmonary entrapment takes place, most if not all the 
administered Streptokinase would have left the 
circulation and thereby would have been unable to have 
any effect on fibrin clot formed as a result of tumour 
cell entrapment.
Streptokinase administered 30 minutes after the 
initial injection of tumour cells and factor complex, 
returned metastases to control levels, thereby 
abolishing the effect of tumour enhancement. This effect 
of tumour burden reduction was still present, although 
to a lesser degree, when Streptokinase was administered 
intravenously at 300 minutes. These results suggest that 
the phenomenon of enhancement of tumour metastasis with 
factor complex II, IX, X, requires the formation of a 
fibrin clot. Destruction of the fibrin clot with 
fibrinolytic agents reverses this effect.
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This intriguing result raises an important question: 
does fibrinolytic therapy have any effect on pulmonary 
tumour seeding in the absence of the exogenous factor 
complex II, IX, X in our animal model? Should 
fibrinolysis inhibit metastasis, it might have a role to 
play in the management of the cancer patient.
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CHAPTER 7. 
STUDIES TO DETERMINE THE EFFECT OF FIBRINOLYSIS ON 
PULMONARY TUMOUR SEEDING.
INTRODUCTION:
The presence of fibrin in malignant tumours has 
attracted considerable attention and the significance of 
it’s presence has been subject to several 
interpretations. Fibrin is an early and consistent
marker of tumour cell stroma. It is deposited within
hours of tumour implantation and remains in the tumour 
throughout the period of tumour growth (Dvorak et al,
1984). Circulating tumour cells may form aggregates with 
platelets and fibrin which facilitate their trapping 
within the microcirculation of target organs, thereby 
enhancing their metastatic effeciency (Crissman, 1984). 
Currently it is believed that fibrin may facilitate
adhesion of tumour cells to vascular endothelium by 
acting as an "intercellular" glue (Francis, 1989).
Our previous experiments have strongly suggested 
that Factor Complex II, IX, X enhances pulmonary tumour 
seeding by increasing tumour cell entrapment within a 
fibrin clot and this effect of tumour enhancement can be 
reversed by activation of the intrinsic fibrinolytic 
system on administration of a "clot-lysis" dose of 
intravenous Streptokinase.
This intriguing result raises two important 
questions:
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1. Does Streptokinase reduce pulmonary tumour seeding in 
a dose-dependent manner?
2. Does fibrinolytic therapy have any effect on 
pulmonary tumour seeding in the absence of exogenous 
coagulation factor complex II, IX, X?
The answer to the second question should bring our 
model closer to the situation that is seen in clinical 
cancer patients.
EXPERIMENT 1: Studies to determine whether the effect of 
Streptokinase on pulmonary tumour seeding is dose- 
dependent .
MATERIALS AND METHODS:
5 groups of female Fischer 344 rats, 6 per group, 6-8 
weeks old were used in this experiment. Animals received 
a single tail vein injection of a 0.5 ml suspension of 
104 Mtln3 cells in F10/DMEM. Additional treatment was 
then commenced as follows:
Group A: These animals received no additional treatment. 
Group B: These animals received an intravenous injection 
of Factor Complex II, IX, X at the same time as 
tumour cell injection (t=0 minutes).
Group C: These animals received Factor Complex at t=0 
minutes and an intravenous injection of 
Streptokinase (30,000 U/Kg), 30 minutes after 
tumour cell injection (t=30)
Group D: These animals received Factor Complex at t=0
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minutes and Streptokinase (15,000 U/Kg) at t=30 
minutes.
Group E: These animals received Factor Complex at t=0
minutes and Streptokinase (3,000 U/Kg) at t=30 
minutes.
The dose of Factor Complex II, IX, X used was 
similar to that used in previous experiments (6:7:6 
Units).
Animals were sacrificed at 17 days and tumour 
nodules assessed by the method of Wexler (Chapter 1).
RESULTS:
As expected, Factor Complex II, IX, X, enhanced 
pulmonary tumour seeding when compared with controls 
(p=0.0204, Groups A vs B). Streptokinase significantly 
reduced pulmonary tumour seeding in all the remaining 
groups in a dose-dependent manner, effective even at 
l/10th the standard "clot-lysis" dose (3000 U/Kg, Groups 
B vs E, median 134 vs 63 seedlings; p=0.0204) (Figure 
16) .
EXPERIMENT 2: Studies to determine the effect of
Streptokinase on pulmonary tumour seeding in the absence 
of exogenous coagulation factor complex II, IX, X.
MATERIALS AND METHODS: 2 groups of 12 female Fischer 344 
rats, 6-8 weeks old, were used in this experiment. Under 
general anaesthesia, animals were given tail vein
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injections of a 0.5 ml suspension of 10^ Mtln^ cells. 
Additional treatment was then commenced as follows:
Group A: These animals received no additional treatment. 
Group B: These animals received a single intravenous
injection of Streptokinase in a dose of 30,000 
U/kg, 30 minutes after tumour cell injection.
Animals were sacrificed at 17 days and pulmonary 
nodules assessed by the method of Wexler.
Comparison of the 2 groups was made using the Mann- 
Whitney test.
RESULTS:
Intravenous Streptokinase, administered 30 minutes after 
tumour cell injection, caused a threefold decrease in 
the number of pulmonary tumour nodules seen (median 23.0 
seedlings in the Streptokinase-treated group vs 67.5 in 
untreated controls; p<0.0001) (Figure 17).
DISCUSSION:
In our previous experiments we showed that factor 
complex II, IX, X enhanced pulmonary tumour seeding and 
that intravenous Streptokinase administered in a "clot- 
lysis" dose of 30,000 U/Kg, 30 minutes after tumour cell 
injection, abolished this effect of pulmonary tumour 
enhancement. The purpose of this study was to assess 
whether this effect of Streptokinase is "dose- 
dependent" . The results of the first experiment 
demonstrate that the effect of Streptokinase in reducing
G
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pulmonary tumour burden is dose-related, the maximal 
effect being achieved using a "clot-lysis" dose of 
30, 000 U/Kg. It is worth noting that even l/10t L^ of the 
"clot-lysis" dose of Streptokinase produced a 
significant reduction in tumour cell burden. This would 
be of considerable significance in the clinical 
situation.
The results of the second experiment are striking. 
Even in the absence of factor complex II, IX, X, a 
"clot-lysis" dose of Streptokinase produced a dramatic 
reduction in tumour cell burden, when administered as an 
intravenous bolus, 30 minutes after tumour cell 
injection. This finding raises interesting questions as 
to whether there is a role for Streptokinase in the 
management of cancer patients.
It is believed that during resection of a primary 
tumour, malignant cells are shed into the bloodstream. 
Some of these cells may get trapped in the 
microcirculation of target organs. Provided the "soil" 
is favourable, some of these tumour cells develop into 
metastasis. The "no-touch" technique in the resection of 
colo-rectal cancer, as advocated by Turnbull (1967) was 
based on the principle of avoiding tumour cell shedding 
at the time of surgery. This technique has largely been 
abandoned because of poor reproducibility, but the 
theory underlying it has not been convincingly refuted.
Tumour cells may therefore be shed into the 
circulation intra-operatively and trapped within a mesh 
of platelets and fibrin at the level of the capillary
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bed of target organs. Fibrinolytic agents administered 
peri-operatively would facilitate destruction of this 
fibrin clot, thereby preventing tumour cell seeding. 
Anti-metastatic therapy has been tried with a varying 
degree of success (Zacharski et al, 1982, 1984;
Zacharski, 1981, 1986b), but adequate controlled studies 
on a suitable population have not been performed. 
Previous work by White et al (1976), using urokinase to 
facilitate fibrinolysis in human cancer, suggests that 
prevention of implantation of circulating malignant 
cells onto vascular endothelium, is likely to improve 
patient survival. The practical benefits of 
antimetastatic measures is difficult to evaluate because 
the metastases prevented are likely to be relatively few 
compared to those which have already occurred before 
surgery. Large prospective studies would therefore be 
necessary to determine the value of antimetastatic 
therapy, but if a simple, safe treatment were available, 
such studies might be justified.
Fibrinolytic agents are attractive in theory. There 
are however a few disadvantages. Streptokinase is 
antigenic and immunogenic in humans. Tissue-plasminogen 
activator (t-PA) , produced by recombinant DNA technology 
(Pennica et al, 1983), would be a more suitable 
alternative. The risk of haemorrhage with the use of 
fibrinolytic agents peri-operatively should also be 
considered. Our experiments have shown that a single 
"clot-lysis" dose is sufficient to inhibit metastasis. 
Monitoring of coagulation showed no systemic disturbance
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of the coagulation system. Furthermore, low-dose 
Streptokinase was also effective in reducing tumour 
seeding in the model incorporating factor complex 
treatment. Whether this remains the case in the absence 
of this treatment is not yet known.
Further work needs to be performed to investigate 
the role of other fibrinolytic agents with regard to 
inhibiting tumour metastasis.
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Final Discussion
The individual studies presented in this thesis have 
been fully discussed in the relevant chapters and this 
final section therefore represents an overview of the 
interaction between coagulation and cancer, 
incorporating the findings of the present work.
The evidence accumulated from previous studies, and 
discussed in the introductory section of this work, 
suggests a two-way interaction between cancer and the 
coagulation system. On the one hand, evidence exists for 
activation of the coagulation system in patients with 
cancer and for the ability of tumour cells to cause such 
activation. On the other hand, there is evidence from 
animal studies and a few human clinical studies to 
suggest that coagulation plays an important role in the 
metastatic process, and that the potential for 
influencing metastasis exists. Given these facts, it is 
easy to speculate that tumours promote their own 
metastasis by virtue of their activation of the 
coagulation system. If this is true, it raises the 
possibility of therapeutically interfering with the 
coagulation system in order to influence the metastatic 
process of malignant tumours, in the clinical situation.
Studies based on animal models are subject to many 
potential sources of error arising from the complexity 
of the variations between different species. As a result 
of this, it is rarely possible to exclude all influences 
other than those with which the experiment is primarily 
concerned. This series of experiments was no exception
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and some of the possible sources of error in the 
individual experiments performed have been described and 
discussed in the relevant chapters. In these 
circumstances, the conclusions reached from individual 
experiments have to take into consideration other 
possible explanations and caution must be exercised in 
interpretation of results. All the experiments described 
in the foregoing chapters were repeated in order to 
ensure that the results obtained were reproducible. 
Equally the importance of mutually supportive findings 
from separate experiments cannot be overemphasised. Such 
independent confirmation increases the confidence with 
which conclusions are made and permits a greater 
accuracy in interpretation of findings, since two 
independent methods of determining the same result are 
much less likely to be in error than one method however 
often repeated. In the present series of studies, 
mutually supportive findings from separate experiments 
provided evidence for all the major points in our 
conclusions. The picture of the cancer/coagulation 
relationship is complex and subtle and the present 
studies have investigated only a few aspects of this 
complex relationship.
Our initial task was to validate the metastatic 
tumour model. Having achieved this, it was important to 
confirm the findings of previous workers, that the 
warfarin-dependent coagulation factor complex II, IX, X, 
enhanced pulmonary tumour seeding in this animal model. 
Studies critically analysing the dose and time of
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administration of the factor complex were performed. The 
results of these studies validated the dose of factor 
complex previously used, and confirmed that the factor 
complex II, IX, X significantly enhanced pulmonary 
tumour seeding. The mechanism of tumour enhancement 
remained unclear. Several possibilities existed. The 
fact that human coagulation factors were producing this 
effect in an animal model raised the possibility of this 
effect being secondary to the xenogeneic nature of the 
factor complex. A comparison of the prometastatic effect 
of human and rat factor complexes showed that this 
effect of tumour enhancement was produced to an equal 
degree, suggesting that the xenogeneic nature of the 
human factor complex was not responsible for producing 
this effect of tumour enhancement.
Further questions could then be addressed. Previous 
work had left open the possibility that one of the three 
factors II, IX, X, was solely responsible for this 
effect of tumour enhancement. Until recently, the 
factors II, IX, X could not be obtained individually in 
a pure form. The ability to obtain these purified 
factors allowed us to demonstrate that all three factors 
when given either individually or in different 
combinations, produced an equal enhancing effect on 
pulmonary tumour seeding. The three factors involved 
occupy a central part in the coagulation cascade, the 
site where the extrinsic and intrinsic system meet to 
form the common pathway. The most distal of these three 
factors in the coagulation "cascade" is factor II
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(prothrombin). Our working hypothesis at this stage was 
that the factor complex probably caused activation of 
the coagulation system via factors IX, X and II (in that 
order), resulting in the formation of a fibrin clot 
which by increasing tumour cell entrapment in a fibrin 
mesh within the pulmonary microcirculation, caused 
enhanced pulmonary tumour seeding.
To test this hypothesis, we needed to answer two 
questions:
1. Does the factor complex II, IX, X activate 
coagulation in this animal model?
2. Is there increased pulmonary entrapment of tumour 
cells on administration of the factor complex?
The study designed to answer the first of these 
questions was complex and difficult. Fibrinopeptide A 
(FpA) is a highly sensitive indicator of activation of 
coagulation. An attempt at analysis of rat urinary FpA 
proved unsuccessful as a result of contamination of 
samples with blood. Analysis of rat plasma FpA was more 
successful. This study demonstrated that factor complex 
II, IX, X when administered alone or along with tumour 
cells activated coagulation. There was a suggestion that 
tumour cells may on their own be responsible for an 
activation of coagulation, though in this study it was 
not shown to be of any significance.
In order to assess pulmonary entrapment of tumour 
cells, the passage of radiolabelled cells through the 
lungs was studied. The results of this study showed a 
20% increase in the number of tumour cells trapped in
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the pulmonary microcirculation, when administered along 
with factor complex II, IX, X.
If fibrin clot formation is required to facilitate 
increased tumour cell entrapment, then destruction of 
fibrin should result in abolition of this effect. 
Streptokinase, a thrombolytic agent when administered in 
a "clot-lysis" dose, succeeded in abolishing this effect 
of tumour enhancement. In order to be effective in our 
model, Streptokinase had to be administered 30 minutes 
after tumour cell injection. The results of this study 
supported our earlier hypothesis that fibrin clot 
formation is required to promote pulmonary tumour 
seeding. It also raised the possibility of considering 
the use of Streptokinase in clinical cancer patients.
A further final study required to be performed to 
answer the question: In the absence of exogenous
coagulation factors II, IX, X, is Streptokinase
effective in inhibiting pulmonary metastasis? The 
results of our study showed that Streptokinase inhibited 
pulmonary tumour seeding in this animal model even in 
the absence of exogenous coagulation factors.
There are several areas of our investigation which 
require further clarification. The association of fibrin 
and tumour cells within the microvasculature has not 
been conclusively proven in this model. Also, 
pathological evidence for intravascular dissolution of
thrombus has not been demonstrated. These studies would
entail extensive microscopic studies of changes in the 
pulmonary microvasculature under the experimental
155
conditions described earlier. In the absence of
histological evidence for our hypothesis that
Streptokinase reduces pulmonary tumour seeding by 
thrombolysis, we cannot exclude the possibility that 
Streptokinase may cause this effect via a completely 
different mechanism, although an overall view of the 
evidence presented makes this seem unlikely. 
Furthermore, we are aware that the behaviour of 
"artificial" metastases by intravenous tumour cell 
injection may be quite different from spontaneous
metastases arising from a primary tumour. However, the 
animal model we used in all our experiments permitted us 
to examine the "intravascular" phase of the metastatic 
process in greater detail than would otherwise have been 
possible.
Our investigations have led us to an interesting 
conclusion: Streptokinase inhibits tumour seeding. Is
this finding significant with regard to the practical 
management of clinical cancer patients? It is widely 
believed that during the resection of a primary tumour, 
malignant cells are shed into the circulation (Engell 
HC, 1955). Some of these circulating cells may arrest at 
the level of the microcirculation of target organs. 
Provided the "soil" is favourable, these cells may 
develop into metastatic deposits. Activation of 
coagulation, as a direct consequence of surgery, would 
theoretically encourage tumour cell entrapment at the 
level of the microcirculation of target organs. Indeed 
animal experimental models have shown that surgical
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stress enhances tumour metastasis (Buinauskas P, et al, 
1958) . If tumour cells that are shed at the time of 
surgery are prevented from adhering to vascular 
endothelium and are kept in circulation, they will 
eventually die. This will reduce the number of 
potentially metastatic cells in the circulation. 
Fibrinolytic therapy administered in the peri-operative 
period would be theoretically effective in this respect. 
There are however a few potential disadvantages with 
fibrinolytic therapy that require serious consideration. 
These are the antigenicity and immunogen i city of 
Streptokinase and the potential risk of haemorrhage 
post-operatively. With regard to the latter problem, 
our animal work demonstrated two encouraging findings:
1. There was no evidence of an overall systemic 
disturbance of coagulation with the dose of 
Streptokinase used.
2. Streptokinase was effective in inhibiting pulmonary 
tumour seeding, even when administered at l/lO*1*1 the 
"clot-lysis" dose.
The use of tissue plasminogen activator, obtained 
by recombinant DNA technology (Pennica et al, 1983), 
would avoid the former complication. Further animal 
experimental work needs to be performed to investigate 
the role of tissue plasminogen activator in inhibiting 
tumour seeding.
Most cancer patients die from tumour metastasis. 
The prevention of metastasis is therefore an important 
goal of cancer research. Evidence to date strongly
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suggests that manipulation of the coagulation system can 
influence the metastatic process in favour of the host. 
A prospective clinical trial is now required to assess 
the role of antimetastatic therapy in clinical cancer 
patients. There are several practical difficulties in 
such a trial; for eg. potential complications arising in 
post-operative patients as a result of fibrinolytic 
therapy, potential antigen/antibody reactions if 
Streptokinase is to be used and the recognition that 
careful interpretation of results based on disease stage 
is essential, taking into consideration that some 
patients will have occult metastases at the time of 
surgery. These problems however, are not insurmountable. 
Despite these apparent difficulties, the potential 
benefits of such a trial could have an impact on the 
management of the patient with malignant disease.
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